<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41532453</PMID><DateRevised><Year>2026</Year><Month>01</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2042-3306</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2026</Year><Month>Jan</Month><Day>14</Day></PubDate></JournalIssue><Title>Equine veterinary journal</Title><ISOAbbreviation>Equine Vet J</ISOAbbreviation></Journal><ArticleTitle>Vonoprazan pharmacokinetics and effects on gastric pH following administration to fed and fasted horses.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/evj.70128</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Current treatment options for equine gastric ulcer syndrome (EGUS), such as omeprazole-a proton pump inhibitor (PPI)-have notable limitations, including the need for administration on an empty stomach. Potassium-competitive acid blockers (P-CABs), such as vonoprazan, are a newer class of acid suppressants that offer several advantages over PPIs in humans and may provide similar benefits in horses.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To describe the pharmacokinetics and effect of a single oral dose of vonoprazan on intragastric pH in horses. We hypothesised that vonoprazan would follow linear kinetics across the doses studied and effectively increase intragastric pH.</AbstractText><AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Prospective, randomised four-way balanced crossover study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Six horses received vonoprazan (0.5 and 1&#x2009;mg/kg), omeprazole (4&#x2009;mg/kg) and water (60&#x2009;mL). Blood samples were collected prior to and up to 72&#x2009;h post-administration. Plasma vonoprazan concentrations were measured using liquid chromatography-tandem mass spectrometry, and non-compartmental and compartmental pharmacokinetic analyses were performed. Intragastric pH was continuously recorded 12&#x2009;h before and 24&#x2009;h after each treatment. The percentage of time pH remained above 4 was compared among treatments.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For 0.5 and 1&#x2009;mg/kg vonoprazan, respectively, C<sub>max</sub> was 23.7&#x2009;&#xb1;&#x2009;14.0 and 55.8&#x2009;&#xb1;&#x2009;18.1&#x2009;ng/mL (mean&#x2009;&#xb1;&#x2009;SD); T<sub>max</sub> was 0.875 (0.25-3.0) and 0.625 (0.08-1.0) h (median and range); and terminal half-life was 6.12&#x2009;&#xb1;&#x2009;1.65 and 6.29&#x2009;&#xb1;&#x2009;1.86&#x2009;h (mean&#x2009;&#xb1;&#x2009;SD). At 1&#x2009;mg/kg, vonoprazan significantly increased the percentage of time pH &gt;4 compared to pre-treatment (91.85% vs. 85.5%; p&#x2009;=&#x2009;0.007) and placebo (90.28&#x2009;&#xb1;&#x2009;5.6% vs. 5.68&#x2009;&#xb1;&#x2009;39%; p&#x2009;=&#x2009;0.021).</AbstractText><AbstractText Label="MAIN LIMITATION" NlmCategory="CONCLUSIONS">Small sample size which may impact clinical applicability of observed changes and potential variability in pH probe positioning.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Vonoprazan was well tolerated and effectively increased and maintained intragastric pH above 4 at the 1&#x2009;mg/kg dose in horses.</AbstractText><CopyrightInformation>&#xa9; 2026 The Author(s). Equine Veterinary Journal published by John Wiley &amp; Sons Ltd on behalf of EVJ Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Camilo J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0002-6227-8572</Identifier><AffiliationInfo><Affiliation>K. L. Maddy Equine Analytical Chemistry Laboratory (Pharmacology Section), School of Veterinary Medicine, University of California, Davis, Davis, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sykes</LastName><ForeName>Benjamin W</ForeName><Initials>BW</Initials><Identifier Source="ORCID">0000-0002-0505-6228</Identifier><AffiliationInfo><Affiliation>BW Sykes Consultancy, Coffs Harbour, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKemie</LastName><ForeName>Daniel S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>K. L. Maddy Equine Analytical Chemistry Laboratory (Pharmacology Section), School of Veterinary Medicine, University of California, Davis, Davis, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kass</LastName><ForeName>Philip H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Department of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, Davis, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knych</LastName><ForeName>Heather K</ForeName><Initials>HK</Initials><Identifier Source="ORCID">0000-0002-8676-4970</Identifier><AffiliationInfo><Affiliation>K. L. Maddy Equine Analytical Chemistry Laboratory (Pharmacology Section), School of Veterinary Medicine, University of California, Davis, Davis, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, Davis, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>UC Davis Center for Equine Health</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>01</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Equine Vet J</MedlineTA><NlmUniqueID>0173320</NlmUniqueID><ISSNLinking>0425-1644</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acid blocker</Keyword><Keyword MajorTopicYN="N">gastric ulcers</Keyword><Keyword MajorTopicYN="N">horse</Keyword><Keyword MajorTopicYN="N">novel treatment</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword><Keyword MajorTopicYN="N">vonoprazan</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>14</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>1</Month><Day>14</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41532453</ArticleId><ArticleId IdType="doi">10.1111/evj.70128</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Sykes BW, Hewetson M, Hepburn RJ, Luthersson N, Tamzali Y. European College of Equine Internal Medicine Consensus Statement&#x2014;Equine Gastric Ulcer Syndrome in Adult Horses. J Vet Intern Med. 2015;29(5):1288&#x2013;1299. https://doi.org/10.1111/jvim.13578</Citation></Reference><Reference><Citation>Vokes J, Lovett A, Sykes B. Equine gastric ulcer syndrome: an update on current knowledge. Animals (Basel). 2023;13(7): 1&#x2013;25. https://doi.org/10.3390/ani13071261</Citation></Reference><Reference><Citation>Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, et al. Characterization of a novel potassium&#x2010;competitive acid blocker of the gastric H,K&#x2010;ATPase, 1&#x2010;[5&#x2010;(2&#x2010;fluorophenyl)&#x2010;1&#x2010;(pyridin&#x2010;3&#x2010;ylsulfonyl)&#x2010;1H&#x2010;pyrrol&#x2010;3&#x2010;yl]&#x2010;N&#x2010;methylmethanamine monofumarate (TAK&#x2010;438). J Pharmacol Exp Ther. 2011;339(2):412&#x2013;420. https://doi.org/10.1124/jpet.111.185314</Citation></Reference><Reference><Citation>Oshima T, Miwa H. Potent potassium&#x2010;competitive acid blockers: a new era for the treatment of acid&#x2010;related diseases. J Neurogastroenterol Motil. 2018;24(3):334&#x2013;344. https://doi.org/10.5056/jnm18029</Citation></Reference><Reference><Citation>Laine L, Sharma P, Mulford DJ, Hunt B, Leifke E, Smith N, et al. Pharmacodynamics and pharmacokinetics of the potassium&#x2010;competitive acid blocker vonoprazan and the proton pump inhibitor lansoprazole in US subjects. Am J Gastroenterol. 2022;117(7):1158&#x2013;1161. https://doi.org/10.14309/ajg.0000000000001735</Citation></Reference><Reference><Citation>Sykes BW, Underwood C, Greer R, McGowan CM, Mills PC. The effects of dose and diet on the pharmacodynamics of omeprazole in the horse. Equine Vet J. 2017;49(4):525&#x2013;531. https://doi.org/10.1111/evj.12630</Citation></Reference><Reference><Citation>Sykes BW, Underwood C, McGowan CM, Mills PC. The effects of dose and diet on the pharmacokinetics of omeprazole in the horse. J Vet Pharmacol Ther. 2017;40(2):172&#x2013;178. https://doi.org/10.1111/jvp.12345</Citation></Reference><Reference><Citation>Mulford DJ, Leifke E, Hibberd M, Howden CW. The effect of food on the pharmacokinetics of the potassium&#x2010;competitive acid blocker vonoprazan. Clin Pharmacol Drug Dev. 2022;11(2):278&#x2013;284. https://doi.org/10.1002/cpdd.1009</Citation></Reference><Reference><Citation>Sugano K. Vonoprazan fumarate, a novel potassium&#x2010;competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol. 2018;11:1756283X17745776. https://doi.org/10.1177/1756283X17745776</Citation></Reference><Reference><Citation>Merritt AM, Sanchez LC, Burrow JA, Church M, Ludzia S. Effect of GastroGard and three compounded oral omeprazole preparations on 24 h intragastric pH in gastrically cannulated mature horses. Equine Vet J. 2003;35(7):691&#x2013;695. https://doi.org/10.2746/042516403775696339</Citation></Reference><Reference><Citation>Sykes BW, Kathawala K, Song Y, Garg S, PAge SW, Underwood C, et al. Preliminary investigations into a novel, long&#x2010;acting, injectable, intramuscular formulation of omeprazole in the horse. Equine Vet J. 2017;49(6):795&#x2013;801. https://doi.org/10.1111/evj.12688</Citation></Reference><Reference><Citation>Echizen H. The first&#x2010;in&#x2010;class potassium&#x2010;competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016;55(4):409&#x2013;418. https://doi.org/10.1007/s40262-015-0326-7</Citation></Reference><Reference><Citation>Aristizabal F, Nieto J, Yamout S, Snyder J. The effect of a hay grid feeder on feed consumption and measurement of the gastric pH using an intragastric electrode device in horses: a preliminary report. Equine Vet J. 2014;46(4):484&#x2013;487. https://doi.org/10.1111/evj.12175</Citation></Reference><Reference><Citation>Otake K, Sakurai Y, Nishida H, Fukui H, Tagawa Y, Yamasaki H, et al. Characteristics of the novel potassium&#x2010;competitive acid blocker vonoprazan fumarate (TAK&#x2010;438). Adv Ther. 2016;33(7):1140&#x2013;1157. https://doi.org/10.1007/s12325-016-0345-2</Citation></Reference><Reference><Citation>Kong W&#x2010;M, Sun B&#x2010;B, Wang Z&#x2010;J, Zheng X&#x2010;K, Zhao K&#x2010;J, Chen Y, et al. Physiologically based pharmacokinetic&#x2013;pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous/oral administration to rats, dogs and humans. Acta Pharmacol Sin. 2020;41(6):852&#x2013;865. https://doi.org/10.1038/s41401-019-0353-2</Citation></Reference><Reference><Citation>Jenkins H, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK&#x2010;438 (vonoprazan), a novel potassium&#x2010;competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41(7):636&#x2013;648. https://doi.org/10.1111/apt.13121</Citation></Reference><Reference><Citation>Scarpignato C, Hunt RH. Potassium&#x2010;competitive acid blockers: current clinical use and future developments. Curr Gastroenterol Rep. 2024;26(11):273&#x2013;293. https://doi.org/10.1007/s11894-024-00939-3</Citation></Reference><Reference><Citation>Scarpignato C, Leifke E, Smith N, Mulford DJ, Lahu G, Facius A, et al. A population pharmacokinetic model of vonoprazan: evaluating the effects of race, disease status, and other covariates on exposure. J Clin Pharmacol. 2022;62(6):801&#x2013;811. https://doi.org/10.1002/jcph.2019</Citation></Reference><Reference><Citation>Wise JC, Hughes KJ, Edwards S, Jacobson GA, Narkowicz CK, Raidal SL. Pharmacokinetic and pharmacodynamic effects of 2 registered omeprazole preparations and varying dose rates in horses. J Vet Intern Med. 2021;35(1):620&#x2013;631. https://doi.org/10.1111/jvim.15971</Citation></Reference><Reference><Citation>Iwakiri K, Sakurai Y, Shiino M, Okamoto H, Kudou K, Nishimura A, et al. A randomized, double&#x2010;blind study to evaluate the acid&#x2010;inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton&#x2010;pump inhibitor&#x2010;resistant erosive esophagitis. Therap Adv Gastroenterol. 2017;10(6):439&#x2013;451. https://doi.org/10.1177/1756283X17705329</Citation></Reference><Reference><Citation>Gong H, Han D, Liu S, Liu C, Zhu X, Chen D. Adverse events of vonoprazan in the treatments of acid&#x2010;related diseases: a systematic review and meta&#x2010;analysis. Rev Esp Enferm Dig. 2023;115(6):294&#x2013;300. https://doi.org/10.17235/reed.2022.9228/2022</Citation></Reference><Reference><Citation>Hodgson E, Thirouin M, Narayanan P, Romano T&#x2010;R, Wise J, Bond S. A novel placement method of a calibration&#x2010;free pH capsule for continuous wireless measurement of intragastric pH in horses. J Vet Intern Med. 2025;39(1):e17273. https://doi.org/10.1111/jvim.17273</Citation></Reference><Reference><Citation>Hou X, Wang J, Du Q, Tian D, Hu N, Liu D, et al. Efficacy and safety of vonoprazan&#x2010;based quadruple therapy for the eradication of helicobacter pylori in patients with peptic ulcers: a pooled analysis of two randomized, double&#x2010;blind, double&#x2010;dummy, phase 3 trials. Biol Pharm Bull. 2024;47(8):1405&#x2013;1414. https://doi.org/10.1248/bpb.b24-00011</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41513155</PMID><DateCompleted><Year>2026</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2026</Year><Month>01</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3441</ISSN><JournalIssue CitedMedium="Internet"><Volume>220</Volume><PubDate><Year>2026</Year><Month>Mar</Month></PubDate></JournalIssue><Title>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</Title><ISOAbbreviation>Eur J Pharm Biopharm</ISOAbbreviation></Journal><ArticleTitle>Enhancing bioavailability of a weakly basic drug through cocrystallization: PBPK modeling of ketoconazole-succinic acid.</ArticleTitle><Pagination><StartPage>114986</StartPage><MedlinePgn>114986</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejpb.2026.114986</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0939-6411(26)00007-X</ELocationID><Abstract><AbstractText>Pharmaceutical cocrystals, formed by combining an active pharmaceutical ingredient (API) with a suitable coformer, offer a promising strategy to enhance drug solubility, stability, and dissolution, thereby improving absorption and bioavailability without altering pharmacological properties. This approach is particularly advantageous for poorly soluble drugs such as ketoconazole (KTZ), a BCS Class II compound characterized by dissolution-limited absorption and variable oral bioavailability. As a weak dibasic drug, KTZ exhibits pH-dependent dissolution, which was favored under acidic gastric conditions. To overcome the pH-dependent dissolution, a cocrystal of KTZ with succinic acid (SA) was developed and a physiologically based pharmacokinetic (PBPK) approach informed by in vitro solubility and dissolution data was used to predict KTZ plasma concentration profiles, following administration of KTZ or KTZ-SA cocrystal. The developed PBPK model was verified, with a predicted/observed AUC ratio within a 2-fold range for KTZ. The model successfully captured the reduced exposure to KTZ when administered with omeprazole. PBPK simulations demonstrated a reduced KTZ exposure following a 200&#xa0;mg dose under achlorhydric conditions (AUC: 1.1&#xa0;&#xb5;g&#xb7;h&#xb7;mL-1) or with omeprazole administration (AUC: 3.1&#xa0;&#xb5;g&#xb7;h&#xb7;mL-1), compared to healthy subjects (AUC: 12.2&#xa0;&#xb5;g&#xb7;h&#xb7;mL-1). In contrast, KTZ-SA cocrystal achieved consistently similar exposure in healthy subjects (AUC: 17.2&#xa0;&#xb5;g&#xb7;h&#xb7;mL-1), achlorhydric populations (AUC: 18.6&#xa0;&#xb5;g&#xb7;h&#xb7;mL-1), or when coadministered with omeprazole (AUC: 16.9&#xa0;&#xb5;g&#xb7;h&#xb7;mL-1). This model-based approach has demonstrated the potential of KTZ-SA cocrystal to enhance bioavailability in populations with achlorhydria-related disparities, effectively addressing the challenges posed by variable gastric acidity. The findings support the development of pharmaceutical cocrystals to optimize drug delivery and maximize therapeutic outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2026 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Santos Goes</LastName><ForeName>Ana Karolina</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida, 6550 Sanger Road, Orlando, FL 32827, USA; Department of Pharmacy, Universidade Estadual do Centro-Oeste (UNICENTRO), Alameda &#xc9;lio Antonio Dalla Vecchi 838, Guarapuava, PR 85040-167, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soliman</LastName><ForeName>Amira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida, 6550 Sanger Road, Orlando, FL 32827, USA; Department of Pharmacy Practice, Faculty of Pharmacy, Helwan University, Helwan 11795, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowthavarapu</LastName><ForeName>Venkata Krishna</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida, 6550 Sanger Road, Orlando, FL 32827, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Paulo Renato</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Universidade Estadual do Centro-Oeste (UNICENTRO), Alameda &#xc9;lio Antonio Dalla Vecchi 838, Guarapuava, PR 85040-167, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Moraes</LastName><ForeName>Natalia Valadares</ForeName><Initials>NV</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida, 6550 Sanger Road, Orlando, FL 32827, USA. Electronic address: nataliademoraes@ufl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur J Pharm Biopharm</MedlineTA><NlmUniqueID>9109778</NlmUniqueID><ISSNLinking>0939-6411</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>R9400W927I</RegistryNumber><NameOfSubstance UI="D007654">Ketoconazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>AB6MNQ6J6L</RegistryNumber><NameOfSubstance UI="D019802">Succinic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>KG60484QX9</RegistryNumber><NameOfSubstance UI="D009853">Omeprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007654" MajorTopicYN="Y">Ketoconazole</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019802" MajorTopicYN="Y">Succinic Acid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003460" MajorTopicYN="N">Crystallization</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009853" MajorTopicYN="N">Omeprazole</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioavailability</Keyword><Keyword MajorTopicYN="N">Cocrystal</Keyword><Keyword MajorTopicYN="N">Cocrystalization</Keyword><Keyword MajorTopicYN="N">Ketoconazole</Keyword><Keyword MajorTopicYN="N">PBPK</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2026</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>23</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>1</Month><Day>10</Day><Hour>0</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>1</Month><Day>9</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41513155</ArticleId><ArticleId IdType="doi">10.1016/j.ejpb.2026.114986</ArticleId><ArticleId IdType="pii">S0939-6411(26)00007-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41471097</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2026</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>Pharmacokinetics of CYP2C19- and CYP3A4-Metabolized Drugs in Cirrhosis Using a Whole-Body PBPK Approach.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1582</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics17121582</ELocationID><Abstract><AbstractText><b>Background/Objectives</b>: Cirrhosis significantly alters physiological function and drug metabolism, particularly for medications primarily metabolized by CYP2C19 and CYP3A4. This study aims to establish a physiologically based pharmacokinetic (PBPK) modelling framework capable of predicting pharmacokinetic changes across different stages of cirrhosis, and to determine optimal dosing regimens that achieve drug exposure levels comparable to those in healthy individuals. <b>Methods</b>: We constructed a physiologically based pharmacokinetic (PBPK) model that incorporates six drugs, including omeprazole, lansoprazole, midazolam, ondansetron, verapamil, and alfentanil, which are metabolized primarily by CYP2C19 or CYP3A4. The pharmacokinetics of these drugs following oral or injectable administration were simulated in 1000 virtual healthy subjects, and the PBPK model was validated using clinical data. The model was further adapted to account for physiological changes in cirrhotic patients, extending its application to a population of 1000 virtual patients with liver cirrhosis. <b>Results</b>: Most observed data fell within the 5th and 95th percentiles of the virtual patient simulation results. Additionally, for most simulations, the area under the concentration-time curve (AUC) and peak concentration (C<sub>max</sub>) were within 0.5- to 2-fold of the observed values. Sensitivity analysis indicated that the reduced expression of metabolizing enzymes increased plasma concentrations of drugs, which was a major factor contributing to the elevated drug exposure in patients with cirrhosis. The clinical dosing regimens of the CYP2C19 substrate omeprazole and the CYP3A4 substrate ondansetron were optimized for use in cirrhotic patients. <b>Conclusions</b>: The developed PBPK model successfully predicted the pharmacokinetics of CYP2C19 and CYP3A4 substrates in both healthy individuals and cirrhotic patients and can be effectively used for dose optimization in cirrhotic populations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mu</LastName><ForeName>Ruijing</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center of Drug Metabolism and Pharmacokinetics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Jingjing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center of Drug Metabolism and Pharmacokinetics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaoli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Mianzhu Municipal Health Bureau, Deyang 618200, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Nan</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-7505-5001</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hanyu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center of Drug Metabolism and Pharmacokinetics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Nos. 82204511</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>No. CPU2022QZ21</GrantID><Agency>the "Double First-Class" university project</Agency><Country/></Grant><Grant><GrantID>2022CZBJ042</GrantID><Agency>Top Talent of Changzhou"The 14th Five-Year Plan" High-Level Health Talents Training Project</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CYP2C19</Keyword><Keyword MajorTopicYN="N">CYP3A4</Keyword><Keyword MajorTopicYN="N">dose optimization</Keyword><Keyword MajorTopicYN="N">liver cirrhosis</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword><Keyword MajorTopicYN="N">physiologically based pharmacokinetic model</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>31</Day><Hour>7</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>31</Day><Hour>7</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>31</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>12</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41471097</ArticleId><ArticleId IdType="pmc">PMC12737180</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics17121582</ArticleId><ArticleId IdType="pii">pharmaceutics17121582</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gin&#xe8;s P., Krag A., Abraldes J.G., Sol&#xe0; E., Fabrellas N., Kamath P.S. Liver cirrhosis. Lancet. 2021;398:1359&#x2013;1376. doi: 10.1016/S0140-6736(21)01374-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01374-X</ArticleId><ArticleId IdType="pubmed">34543610</ArticleId></ArticleIdList></Reference><Reference><Citation>Devarbhavi H., Asrani S.K., Arab J.P., Nartey Y.A., Pose E., Kamath P.S. Global burden of liver disease: 2023 update. J. Hepatol. 2023;79:516&#x2013;537. doi: 10.1016/j.jhep.2023.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2023.03.017</ArticleId><ArticleId IdType="pubmed">36990226</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang D.Q., Terrault N.A., Tacke F., Gluud L.L., Arrese M., Bugianesi E., Loomba R. Global epidemiology of cirrhosis&#x2014;Aaetiology, trends and predictions. Nat. Rev. Gastroenterol. Hepatol. 2023;20:388&#x2013;398. doi: 10.1038/s41575-023-00759-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-023-00759-2</ArticleId><ArticleId IdType="pmc">PMC10043867</ArticleId><ArticleId IdType="pubmed">36977794</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Hepatitis Programme.  [(accessed on 4 December 2025)].  Available online:  https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hepatitis.</Citation></Reference><Reference><Citation>Roehlen N., Crouchet E., Baumert T.F. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells. 2020;9:875. doi: 10.3390/cells9040875.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9040875</ArticleId><ArticleId IdType="pmc">PMC7226751</ArticleId><ArticleId IdType="pubmed">32260126</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhar D., Baglieri J., Kisseleva T., Brenner D.A. Mechanisms of liver fibrosis and its role in liver cancer. Exp. Biol. Med. 2020;245:96&#x2013;108. doi: 10.1177/1535370219898141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370219898141</ArticleId><ArticleId IdType="pmc">PMC7016420</ArticleId><ArticleId IdType="pubmed">31924111</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 1973;60:646&#x2013;649. doi: 10.1002/bjs.1800600817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.1800600817</ArticleId><ArticleId IdType="pubmed">4541913</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikawa H., Osaki Y. Liver Cirrhosis: Evaluation, Nutritional Status, and Prognosis. Mediat. Inflamm. 2015;2015:872152. doi: 10.1155/2015/872152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/872152</ArticleId><ArticleId IdType="pmc">PMC4606163</ArticleId><ArticleId IdType="pubmed">26494949</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelmann C., Cl&#xe0;ria J., Szabo G., Bosch J., Bernardi M. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J. Hepatol. 2021;75((Suppl. S1)):S49&#x2013;S66. doi: 10.1016/j.jhep.2021.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2021.01.002</ArticleId><ArticleId IdType="pmc">PMC9272511</ArticleId><ArticleId IdType="pubmed">34039492</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsochatzis E.A., Bosch J., Burroughs A.K. Liver cirrhosis. Lancet. 2014;383:1749&#x2013;1761. doi: 10.1016/S0140-6736(14)60121-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60121-5</ArticleId><ArticleId IdType="pubmed">24480518</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidelines for the Clinical Use of Proton Pump Inhibitors.  [(accessed on 4 December 2025)]; Available online:  https://www.nhc.gov.cn/yzygj/c100068/202012/b59f1401666645009b64aee17185c87b.shtml.</Citation></Reference><Reference><Citation>El Rouby N., Lima J.J., Johnson J.A. Proton pump inhibitors: From CYP2C19 pharmacogenetics to precision medicine. Expert. Opin. Drug Metab. Toxicol. 2018;14:447&#x2013;460. doi: 10.1080/17425255.2018.1461835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17425255.2018.1461835</ArticleId><ArticleId IdType="pmc">PMC5942154</ArticleId><ArticleId IdType="pubmed">29620484</ArticleId></ArticleIdList></Reference><Reference><Citation>Desta Z., Zhao X., Shin J.G., Flockhart D.A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 2002;41:913&#x2013;958. doi: 10.2165/00003088-200241120-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-200241120-00002</ArticleId><ArticleId IdType="pubmed">12222994</ArticleId></ArticleIdList></Reference><Reference><Citation>Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., Walker J.R., Antman E.M., Macias W., Braunwald E., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 2009;360:354&#x2013;362. doi: 10.1056/NEJMoa0809171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0809171</ArticleId><ArticleId IdType="pubmed">19106084</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamdy N.A., Kennedy H.J., Nicholl J., Triger D.R. Sedation for gastroscopy: A comparative study of midazolam and Diazemuls in patients with and without cirrhosis. Br. J. Clin. Pharmacol. 1986;22:643&#x2013;647. doi: 10.1111/j.1365-2125.1986.tb02952.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.1986.tb02952.x</ArticleId><ArticleId IdType="pmc">PMC1401217</ArticleId><ArticleId IdType="pubmed">3552010</ArticleId></ArticleIdList></Reference><Reference><Citation>Duthaler U., Bachmann F., Suenderhauf C., Grandinetti T., Pfefferkorn F., Haschke M., Hruz P., Bouitbir J., Kr&#xe4;henb&#xfc;hl S. Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently. Clin. Pharmacokinet. 2022;61:1039&#x2013;1055. doi: 10.1007/s40262-022-01119-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-022-01119-0</ArticleId><ArticleId IdType="pmc">PMC9287224</ArticleId><ArticleId IdType="pubmed">35570253</ArticleId></ArticleIdList></Reference><Reference><Citation>Delc&#xf2; F., Tchambaz L., Schlienger R., Drewe J., Kr&#xe4;henb&#xfc;hl S. Dose adjustment in patients with liver disease. Drug Saf. 2005;28:529&#x2013;545. doi: 10.2165/00002018-200528060-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002018-200528060-00005</ArticleId><ArticleId IdType="pubmed">15924505</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson T.N., Boussery K., Rowland-Yeo K., Tucker G.T., Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin. Pharmacokinet. 2010;49:189&#x2013;206. doi: 10.2165/11318160-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11318160-000000000-00000</ArticleId><ArticleId IdType="pubmed">20170207</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H., Wei Y., He K., Zhao X., Mu H., Wen Q. Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic model. Eur. J. Pharm. Sci. 2022;179:106298. doi: 10.1016/j.ejps.2022.106298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2022.106298</ArticleId><ArticleId IdType="pubmed">36162752</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalam M.N., Rasool M.F., Alqahtani F., Imran I., Rehman A.U., Ahmed N. Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients. Drug Des. Dev. Ther. 2021;15:1195&#x2013;1211. doi: 10.2147/DDDT.S297981.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S297981</ArticleId><ArticleId IdType="pmc">PMC7982780</ArticleId><ArticleId IdType="pubmed">33762817</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo X., Zhang Z., Mu R., Hu G., Liu L., Liu X. Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects. Pharmaceutics. 2024;16:234. doi: 10.3390/pharmaceutics16020234.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics16020234</ArticleId><ArticleId IdType="pmc">PMC10893190</ArticleId><ArticleId IdType="pubmed">38399287</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan F.X., Reiter M.J., Pritchett E.L., Shand D.G. Verapamil plasma binding: Relationship to alpha 1-acid glycoprotein and drug efficacy. Clin. Pharmacol. Ther. 1983;33:485&#x2013;490. doi: 10.1038/clpt.1983.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.1983.66</ArticleId><ArticleId IdType="pubmed">6831827</ArticleId></ArticleIdList></Reference><Reference><Citation>Belpaire F.M., Bogaert M.G. Binding of alfentanil to human alpha 1-acid glycoprotein, albumin and serum. Int. J. Clin. Pharmacol. Ther. Toxicol. 1991;29:96&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">2071261</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartee N.M.P., Wang M.M. Binding of omeprazole to protein targets identified by monoclonal antibodies. PLoS ONE. 2020;15:e0239464. doi: 10.1371/journal.pone.0239464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0239464</ArticleId><ArticleId IdType="pmc">PMC7500594</ArticleId><ArticleId IdType="pubmed">32946534</ArticleId></ArticleIdList></Reference><Reference><Citation>Landes B.D., Petite J.P., Flouvat B. Clinical pharmacokinetics of lansoprazole. Clin. Pharmacokinet. 1995;28:458&#x2013;470. doi: 10.2165/00003088-199528060-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-199528060-00004</ArticleId><ArticleId IdType="pubmed">7656504</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamaoka N., Oda Y., Hase I., Mizutani K., Nakamoto T., Ishizaki T., Asada A. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study. Clin. Pharmacol. Ther. 1999;66:110&#x2013;117. doi: 10.1053/cp.1999.v66.100038001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/cp.1999.v66.100038001</ArticleId><ArticleId IdType="pubmed">10460064</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson K.H., Hicks F.M. Clinical pharmacokinetics of ondansetron. A review. J. Pharm. Pharmacol. 1996;48:774&#x2013;781. doi: 10.1111/j.2042-7158.1996.tb03973.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2042-7158.1996.tb03973.x</ArticleId><ArticleId IdType="pubmed">8887724</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R., Barton H.A., Maurer T.S. A Mechanistic Pharmacokinetic Model for Liver Transporter Substrates Under Liver Cirrhosis Conditions. CPT Pharmacomet. Syst. Pharmacol. 2015;4:338&#x2013;349. doi: 10.1002/psp4.39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psp4.39</ArticleId><ArticleId IdType="pmc">PMC4505828</ArticleId><ArticleId IdType="pubmed">26225262</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsen S., Fynne L., Gr&#xf8;nb&#xe6;k H., Krogh K. Small intestinal transit in patients with liver cirrhosis and portal hypertension: A descriptive study. BMC Gastroenterol. 2012;12:176. doi: 10.1186/1471-230X-12-176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-12-176</ArticleId><ArticleId IdType="pmc">PMC3520867</ArticleId><ArticleId IdType="pubmed">23216853</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepin X.J.H., Johansson Soares Medeiros J., Deris Prado L., Suarez Sharp S. The Development of an Age-Appropriate Fixed Dose Combination for Tuberculosis Using Physiologically-Based Pharmacokinetic Modeling (PBBM) and Risk Assessment. Pharmaceutics. 2024;16:1587. doi: 10.3390/pharmaceutics16121587.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics16121587</ArticleId><ArticleId IdType="pmc">PMC11680012</ArticleId><ArticleId IdType="pubmed">39771565</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J., Zhang Z., Liu X., Yang H., Liu L. Prediction of Pharmacokinetics for CYP3A4-Metabolized Drugs in Pediatrics and Geriatrics Using Dynamic Age-Dependent Physiologically Based Pharmacokinetic Models. Pharmaceutics. 2025;17:214. doi: 10.3390/pharmaceutics17020214.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics17020214</ArticleId><ArticleId IdType="pmc">PMC11860008</ArticleId><ArticleId IdType="pubmed">40006581</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong W.M., Sun B.B., Wang Z.J., Zheng X.K., Zhao K.J., Chen Y., Zhang J.X., Liu P.H., Zhu L., Xu R.J., et al. Physiologically based pharmacokinetic-pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous/oral administration to rats, dogs and humans. Acta Pharmacol. Sin. 2020;41:852&#x2013;865. doi: 10.1038/s41401-019-0353-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-019-0353-2</ArticleId><ArticleId IdType="pmc">PMC7468366</ArticleId><ArticleId IdType="pubmed">31969689</ArticleId></ArticleIdList></Reference><Reference><Citation>Small B.G., Hatley O., Jamei M., Gardner I., Johnson T.N. Incorporation and Performance Verification of Hepatic Portal Blood Flow Shunting in Minimal and Full PBPK Models of Liver Cirrhosis. Clin. Pharmacol. Ther. 2023;114:1264&#x2013;1273. doi: 10.1002/cpt.3032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.3032</ArticleId><ArticleId IdType="pubmed">37620290</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladumor M.K., Storelli F., Liang X., Lai Y., Enogieru O.J., Chothe P.P., Evers R., Unadkat J.D. Predicting changes in the pharmacokinetics of CYP3A-metabolized drugs in hepatic impairment and insights into factors driving these changes. CPT Pharmacomet. Syst. Pharmacol. 2023;12:261&#x2013;273. doi: 10.1002/psp4.12901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psp4.12901</ArticleId><ArticleId IdType="pmc">PMC9931433</ArticleId><ArticleId IdType="pubmed">36540952</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson T., Reg&#xe5;rdh C.G., Lou Y.C., Zhang Y., Dahl M.L., Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics. 1992;2:25&#x2013;31. doi: 10.1097/00008571-199202000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00008571-199202000-00005</ArticleId><ArticleId IdType="pubmed">1302040</ArticleId></ArticleIdList></Reference><Reference><Citation>Noubarani M., Kobarfard F., Motevalian M., Keyhanfar F. Variation in omeprazole pharmacokinetics in a random Iranian population: A pilot study. Biopharm. Drug Dispos. 2012;33:324&#x2013;331. doi: 10.1002/bdd.1805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bdd.1805</ArticleId><ArticleId IdType="pubmed">22890488</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X.P., Xu J.M., Hu Y.M., Mei Q., Xu X.H. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people. J. Clin. Pharm. Ther. 2007;32:517&#x2013;524. doi: 10.1111/j.1365-2710.2007.00851.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2710.2007.00851.x</ArticleId><ArticleId IdType="pubmed">17875119</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakai T., Aoyama N., Kita T., Sakaeda T., Nishiguchi K., Nishitora Y., Hohda T., Sirasaka D., Tamura T., Tanigawara Y., et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm. Res. 2001;18:721&#x2013;727. doi: 10.1023/A:1011035007591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1011035007591</ArticleId><ArticleId IdType="pubmed">11474773</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuta T., Ohashi K., Kobayashi K., Iida I., Yoshida H., Shirai N., Takashima M., Kosuge K., Hanai H., Chiba K., et al. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin. Pharmacol. Ther. 1999;66:265&#x2013;274. doi: 10.1016/S0009-9236(99)70034-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0009-9236(99)70034-2</ArticleId><ArticleId IdType="pubmed">10511062</ArticleId></ArticleIdList></Reference><Reference><Citation>Rom&#xe1;n M., Ochoa D., S&#xe1;nchez-Rojas S.D., Taleg&#xf3;n M., Prieto-P&#xe9;rez R., Rivas &#xc2;., Abad-Santos F., Cabaleiro T. Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole. Pharmacogenomics. 2014;15:1893&#x2013;1901. doi: 10.2217/pgs.14.141.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/pgs.14.141</ArticleId><ArticleId IdType="pubmed">25495411</ArticleId></ArticleIdList></Reference><Reference><Citation>Cawello W., Mueller-Voessing C., Fichtner A. Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: Results from a phase I, randomized, crossover trial. Clin. Drug Investig. 2014;34:317&#x2013;325. doi: 10.1007/s40261-014-0177-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40261-014-0177-2</ArticleId><ArticleId IdType="pubmed">24567279</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S.K., Kang T.S., Eom S.O., Kim J.I., Lee H.J., Roh J. CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole. J. Clin. Pharm. Ther. 2009;34:437&#x2013;446. doi: 10.1111/j.1365-2710.2008.01012.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2710.2008.01012.x</ArticleId><ArticleId IdType="pubmed">19583677</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho J.Y., Yu K.S., Jang I.J., Yang B.H., Shin S.G., Yim D.S. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br. J. Clin. Pharmacol. 2002;53:393&#x2013;397. doi: 10.1046/j.1365-2125.2002.01366.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2125.2002.01366.x</ArticleId><ArticleId IdType="pmc">PMC1874278</ArticleId><ArticleId IdType="pubmed">11966672</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasui-Furukori N., Takahata T., Nakagami T., Yoshiya G., Inoue Y., Kaneko S., Tateishi T. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br. J. Clin. Pharmacol. 2004;57:487&#x2013;494. doi: 10.1111/j.1365-2125.2003.02047.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.2003.02047.x</ArticleId><ArticleId IdType="pmc">PMC1884483</ArticleId><ArticleId IdType="pubmed">15025747</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussein Z., Granneman G.R., Mukherjee D., Samara E., Hogan D.L., Koss M.A., Isenberg J.I. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br. J. Clin. Pharmacol. 1993;36:391&#x2013;398. doi: 10.1111/j.1365-2125.1993.tb00386.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.1993.tb00386.x</ArticleId><ArticleId IdType="pmc">PMC1364610</ArticleId><ArticleId IdType="pubmed">12959285</ArticleId></ArticleIdList></Reference><Reference><Citation>Amer F., Karol M.D., Pan W.J., Griffin J.S., Lukasik N.L., Locke C.S., Chiu Y.L. Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. Clin. Ther. 2004;26:2076&#x2013;2083. doi: 10.1016/j.clinthera.2004.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2004.12.008</ArticleId><ArticleId IdType="pubmed">15823771</ArticleId></ArticleIdList></Reference><Reference><Citation>Doan T.T., Wang Q., Griffin J.S., Lukasik N.L., O&#x2019;Dea R.F., Pan W.J. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. Am. J. Health Syst. Pharm. 2001;58:1512&#x2013;1519. doi: 10.1093/ajhp/58.16.1512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajhp/58.16.1512</ArticleId><ArticleId IdType="pubmed">11515348</ArticleId></ArticleIdList></Reference><Reference><Citation>Miura M. Enantioselective disposition of lansoprazole and rabeprazole in human plasma. Yakugaku Zasshi. 2006;126:395&#x2013;402. doi: 10.1248/yakushi.126.395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/yakushi.126.395</ArticleId><ArticleId IdType="pubmed">16755125</ArticleId></ArticleIdList></Reference><Reference><Citation>Flouvat B., Delhotal-Landes B., Cournot A., Dellatolas F. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. Br. J. Clin. Pharmacol. 1993;36:467&#x2013;469. doi: 10.1111/j.1365-2125.1993.tb00398.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.1993.tb00398.x</ArticleId><ArticleId IdType="pmc">PMC1364622</ArticleId><ArticleId IdType="pubmed">12959297</ArticleId></ArticleIdList></Reference><Reference><Citation>Delhotal-Landes B., Flouvat B., Duchier J., Molinie P., Dellatolas F., Lemaire M. Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur. J. Clin. Pharmacol. 1993;45:367&#x2013;371. doi: 10.1007/BF00265957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00265957</ArticleId><ArticleId IdType="pubmed">8299672</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian D.D., Leonowens C., Cox E.J., Gonz&#xe1;lez-P&#xe9;rez V., Frederick K.S., Scarlett Y.V., Fisher M.B., Paine M.F. Indinavir Increases Midazolam N-Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo Approach. Drug Metab. Dispos. 2019;47:724&#x2013;731. doi: 10.1124/dmd.119.087007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.119.087007</ArticleId><ArticleId IdType="pmc">PMC6556520</ArticleId><ArticleId IdType="pubmed">31028057</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih P.S., Huang J.D. Pharmacokinetics of midazolam and 1&#x2019;-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab. Dispos. 2002;30:1491&#x2013;1496. doi: 10.1124/dmd.30.12.1491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.30.12.1491</ArticleId><ArticleId IdType="pubmed">12433824</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupferschmidt H.H., Ha H.R., Ziegler W.H., Meier P.J., Kr&#xe4;henb&#xfc;hl S. Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther. 1995;58:20&#x2013;28. doi: 10.1016/0009-9236(95)90068-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0009-9236(95)90068-3</ArticleId><ArticleId IdType="pubmed">7628179</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng R., Butler K. The effect of ticagrelor on the metabolism of midazolam in healthy volunteers. Clin. Ther. 2013;35:1025&#x2013;1037. doi: 10.1016/j.clinthera.2013.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2013.06.003</ArticleId><ArticleId IdType="pubmed">23870610</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T., Mao G.F., Xia D.Y., Su X.Y., Zhao L.S. Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. J. Clin. Pharm. Ther. 2011;36:406&#x2013;411. doi: 10.1111/j.1365-2710.2010.01178.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2710.2010.01178.x</ArticleId><ArticleId IdType="pubmed">21545620</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepper E.R., Hicks J.K., Verweij J., Zhai S., Figg W.D., Sparreboom A. Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection. J. Chromatogr. B. 2004;806:305&#x2013;310. doi: 10.1016/j.jchromb.2004.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchromb.2004.04.003</ArticleId><ArticleId IdType="pubmed">15171944</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale O., Nilsen T., Loftsson T., Hjorth T&#xf8;nnesen H., Klepstad P., Kaasa S., Holand T., Djupesland P.G. Intranasal midazolam: A comparison of two delivery devices in human volunteers. J. Pharm. Pharmacol. 2006;58:1311&#x2013;1318. doi: 10.1211/jpp.58.10.0003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1211/jpp.58.10.0003</ArticleId><ArticleId IdType="pubmed">17034653</ArticleId></ArticleIdList></Reference><Reference><Citation>VanDenBerg C.M., Kazmi Y., Stewart J., Weidler D.J., Tenjarla S.N., Ward E.S., Jann M.W. Pharmacokinetics of three formulations of ondansetron hydrochloride in healthy volunteers: 24-mg oral tablet, rectal suppository, and i.v. infusion. Am. J. Health Syst. Pharm. 2000;57:1046&#x2013;1050. doi: 10.1093/ajhp/57.11.1046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajhp/57.11.1046</ArticleId><ArticleId IdType="pubmed">10876746</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsyu P.H., Pritchard J.F., Bozigian H.P., Lloyd T.L., Griffin R.H., Shamburek R., Krishna G., Barr W.H. Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum. Pharm. Res. 1994;11:156&#x2013;159. doi: 10.1023/A:1018974501232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1018974501232</ArticleId><ArticleId IdType="pubmed">8140047</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard J.F., Bryson J.C., Kernodle A.E., Benedetti T.L., Powell J.R. Age and gender effects on ondansetron pharmacokinetics: Evaluation of healthy aged volunteers. Clin. Pharmacol. Ther. 1992;51:51&#x2013;55. doi: 10.1038/clpt.1992.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.1992.7</ArticleId><ArticleId IdType="pubmed">1531044</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashforth E.I., Palmer J.L., Bye A., Bedding A. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. Br. J. Clin. Pharmacol. 1994;37:389&#x2013;391. doi: 10.1111/j.1365-2125.1994.tb04294.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.1994.tb04294.x</ArticleId><ArticleId IdType="pmc">PMC1364741</ArticleId><ArticleId IdType="pubmed">8018461</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake J.C., Palmer J.L., Minton N.A., Burroughs A.K. The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment. Br. J. Clin. Pharmacol. 1993;35:441&#x2013;443. doi: 10.1111/j.1365-2125.1993.tb04164.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.1993.tb04164.x</ArticleId><ArticleId IdType="pmc">PMC1381558</ArticleId><ArticleId IdType="pubmed">8485026</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominic J.A., Bourne D.W., Tan T.G., Kirsten E.B., McAllister R.G., Jr. The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration. J. Cardiovasc. Pharmacol. 1981;3:25&#x2013;38. doi: 10.1097/00005344-198101000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005344-198101000-00003</ArticleId><ArticleId IdType="pubmed">6160352</ArticleId></ArticleIdList></Reference><Reference><Citation>Hla K.K., Henry J.A., Latham A.N. Pharmacokinetics and pharmacodynamics of two formulations of verapamil. Br. J. Clin. Pharmacol. 1987;24:661&#x2013;664. doi: 10.1111/j.1365-2125.1987.tb03226.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.1987.tb03226.x</ArticleId><ArticleId IdType="pmc">PMC1386339</ArticleId><ArticleId IdType="pubmed">3435694</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadashzadeh S., Javadian B., Sadeghian S. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. Biopharm. Drug Dispos. 2006;27:329&#x2013;334. doi: 10.1002/bdd.512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bdd.512</ArticleId><ArticleId IdType="pubmed">16892180</ArticleId></ArticleIdList></Reference><Reference><Citation>Somogyi A., Albrecht M., Kliems G., Sch&#xe4;fer K., Eichelbaum M. Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br. J. Clin. Pharmacol. 1981;12:51&#x2013;60. doi: 10.1111/j.1365-2125.1981.tb01854.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.1981.tb01854.x</ArticleId><ArticleId IdType="pmc">PMC1401748</ArticleId><ArticleId IdType="pubmed">7248141</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharasch E.D., Hoffer C., Walker A., Sheffels P. Disposition and miotic effects of oral alfentanil: A potential noninvasive probe for first-pass cytochrome P4503A activity. Clin. Pharmacol. Ther. 2003;73:199&#x2013;208. doi: 10.1067/mcp.2003.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mcp.2003.30</ArticleId><ArticleId IdType="pubmed">12621385</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwagmeier R., Boerger N., Meissner W., Striebel H.W. Pharmacokinetics of intranasal alfentanil. J. Clin. Anesth. 1995;7:109&#x2013;113. doi: 10.1016/0952-8180(94)00023-W.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0952-8180(94)00023-W</ArticleId><ArticleId IdType="pubmed">7598917</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrier C., Marty J., Bouffard Y., Haberer J.P., Levron J.C., Duvaldestin P. Alfentanil pharmacokinetics in patients with cirrhosis. Anesthesiology. 1985;62:480&#x2013;484. doi: 10.1097/00000542-198504000-00018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-198504000-00018</ArticleId><ArticleId IdType="pubmed">3920934</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Xie L., Yang L., Jiang L., Yang Y., Zhi H., Liu X., Yang H., Liu L. Prediction of Omeprazole Pharmacokinetics and its Inhibition on Gastric Acid Secretion in Humans Using Physiologically Based Pharmacokinetic-Pharmacodynamic Model Characterizing CYP2C19 Polymorphisms. Pharm. Res. 2023;40:1735&#x2013;1750. doi: 10.1007/s11095-023-03531-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-023-03531-y</ArticleId><ArticleId IdType="pubmed">37226024</ArticleId></ArticleIdList></Reference><Reference><Citation>Nies A.S., Shand D.G., Wilkinson G.R. Altered hepatic blood flow and drug disposition. Clin. Pharmacokinet. 1976;1:135&#x2013;155. doi: 10.2165/00003088-197601020-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-197601020-00005</ArticleId><ArticleId IdType="pubmed">13954</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland M. Protein binding and drug clearance. Clin. Pharmacokinet. 1984;9((Suppl. S1)):10&#x2013;17. doi: 10.2165/00003088-198400091-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-198400091-00002</ArticleId><ArticleId IdType="pubmed">6705422</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapper E.B., Parikh N.D. Diagnosis and Management of Cirrhosis and Its Complications: A Review. JAMA. 2023;329:1589&#x2013;1602. doi: 10.1001/jama.2023.5997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.5997</ArticleId><ArticleId IdType="pmc">PMC10843851</ArticleId><ArticleId IdType="pubmed">37159031</ArticleId></ArticleIdList></Reference><Reference><Citation>Zardi E.M., Abbate A., Zardi D.M., Dobrina A., Margiotta D., Van Tassell B.W., Afeltra A., Sanyal A.J. Cirrhotic cardiomyopathy. J. Am. Coll. Cardiol. 2010;56:539&#x2013;549. doi: 10.1016/j.jacc.2009.12.075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2009.12.075</ArticleId><ArticleId IdType="pubmed">20688208</ArticleId></ArticleIdList></Reference><Reference><Citation>Acalovschi M., Dumitra&#x15f;cu D.L., Csakany I. Gastric and gall bladder emptying of a mixed meal are not coordinated in liver cirrhosis--a simultaneous sonographic study. Gut. 1997;40:412&#x2013;417. doi: 10.1136/gut.40.3.412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.40.3.412</ArticleId><ArticleId IdType="pmc">PMC1027095</ArticleId><ArticleId IdType="pubmed">9135534</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin W., Chen Y., Unadkat J.D., Zhang X., Wu D., Heimbach T. Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective. Pharm. Res. 2022;39:1701&#x2013;1731. doi: 10.1007/s11095-022-03274-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-022-03274-2</ArticleId><ArticleId IdType="pubmed">35552967</ArticleId></ArticleIdList></Reference><Reference><Citation>Loisios-Konstantinidis I., Dressman J. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of In Vivo Clinical Studies: Current Status, Challenges, and Opportunities. Mol. Pharm. 2021;18:1&#x2013;17. doi: 10.1021/acs.molpharmaceut.0c00903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.0c00903</ArticleId><ArticleId IdType="pubmed">33320002</ArticleId></ArticleIdList></Reference><Reference><Citation>Upton R.N., Foster D.J., Abuhelwa A.Y. An introduction to physiologically-based pharmacokinetic models. Paediatr. Anaesth. 2016;26:1036&#x2013;1046. doi: 10.1111/pan.12995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pan.12995</ArticleId><ArticleId IdType="pubmed">27550716</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy M.B., Cabalu T.D., de Zwart L., Ramsden D., Dowty M.E., Taskar K.S., Bad&#xe9;e J., Bolleddula J., Boulu L., Fu Q., et al. Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective. Clin. Pharmacol. Ther. 2025;117:403&#x2013;420. doi: 10.1002/cpt.3477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.3477</ArticleId><ArticleId IdType="pmc">PMC11739743</ArticleId><ArticleId IdType="pubmed">39422118</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Yu Z., Yao X., Lei Z., Zhao K., Wang W., Zhang X., Chen X., Liu D. Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker. Front. Pharmacol. 2022;13:972411. doi: 10.3389/fphar.2022.972411.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.972411</ArticleId><ArticleId IdType="pmc">PMC9543720</ArticleId><ArticleId IdType="pubmed">36210839</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland Yeo K., Gil Berglund E., Chen Y. Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future. Clin. Pharmacol. Ther. 2024;116:563&#x2013;576. doi: 10.1002/cpt.3289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.3289</ArticleId><ArticleId IdType="pubmed">38686708</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgieva M., Xenodochidis C., Krasteva N. Old age as a risk factor for liver diseases: Modern therapeutic approaches. Exp. Gerontol. 2023;184:112334. doi: 10.1016/j.exger.2023.112334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2023.112334</ArticleId><ArticleId IdType="pubmed">37977514</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong S.H., Jang J.H., Lee Y.B. Physiologically Based Pharmacokinetic (PBPK) Modeling of Lornoxicam: Exploration of doses for CYP2C9 Genotypes and Patients with Cirrhosis. J. Pharm. Sci. 2022;111:3174&#x2013;3184. doi: 10.1016/j.xphs.2022.08.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2022.08.035</ArticleId><ArticleId IdType="pubmed">36057318</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgers T., Leahy D., Rowland M. Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases. J. Pharm. Sci. 2005;94:1259&#x2013;1276. doi: 10.1002/jps.20322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.20322</ArticleId><ArticleId IdType="pubmed">15858854</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W., Johnson T.N., Bui K.H., Cheung S.Y.A., Li J., Xu H., Al-Huniti N., Zhou D. Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children. Clin. Pharmacol. Ther. 2018;104:188&#x2013;200. doi: 10.1002/cpt.905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.905</ArticleId><ArticleId IdType="pubmed">29027194</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F., Gaohua L., Zhao P., Jamei M., Huang S.M., Bashaw E.D., Lee S.C. Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: Application to predict drug/genetic interactions. Pharm. Res. 2014;31:1919&#x2013;1929. doi: 10.1007/s11095-013-1293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-013-1293-z</ArticleId><ArticleId IdType="pubmed">24590877</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi F., Zhu L., Li N., Ge T., Xu G., Liao S. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole. Int. J. Antimicrob. Agents. 2017;49:403&#x2013;409. doi: 10.1016/j.ijantimicag.2016.11.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2016.11.025</ArticleId><ArticleId IdType="pubmed">28159656</ArticleId></ArticleIdList></Reference><Reference><Citation>Katashima M., Yamamoto K., Sugiura M., Sawada Y., Iga T. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. Drug Metab. Dispos. 1995;23:718&#x2013;723. doi: 10.1016/S0090-9556(25)06649-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0090-9556(25)06649-8</ArticleId><ArticleId IdType="pubmed">7587960</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanioka N., Tsuneto Y., Saito Y., Maekawa K., Sawada J., Narimatsu S. Influence of CYP2C19*18 and CYP2C19*19 alleles on omeprazole 5-hydroxylation: In vitro functional analysis of recombinant enzymes expressed in Saccharomyces cerevisiae. Basic. Clin. Pharmacol. Toxicol. 2008;102:388&#x2013;393. doi: 10.1111/j.1742-7843.2008.00222.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-7843.2008.00222.x</ArticleId><ArticleId IdType="pubmed">18312490</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.A., Kim M.J., Park J.Y., Shon J.H., Yoon Y.R., Lee S.S., Liu K.H., Chun J.H., Hyun M.H., Shin J.G. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab. Dispos. 2003;31:1227&#x2013;1234. doi: 10.1124/dmd.31.10.1227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.31.10.1227</ArticleId><ArticleId IdType="pubmed">12975331</ArticleId></ArticleIdList></Reference><Reference><Citation>Steere B., Baker J.A., Hall S.D., Guo Y. Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model. Drug Metab. Dispos. 2015;43:870&#x2013;883. doi: 10.1124/dmd.114.061523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.114.061523</ArticleId><ArticleId IdType="pubmed">25845826</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki H., Inoue K., Shaw P.M., Checovich W.J., Guengerich F.P., Shimada T. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples. J. Pharmacol. Exp. Ther. 1997;283:434&#x2013;442. doi: 10.1016/S0022-3565(24)37072-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3565(24)37072-7</ArticleId><ArticleId IdType="pubmed">9353355</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanke N., Turk D., Selzer D., Wiebe S., Fernandez &#xc9;., Stopfer P., Nock V., Lehr T. A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug-Drug Interaction Studies. Pharmaceutics. 2020;12:556. doi: 10.3390/pharmaceutics12060556.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12060556</ArticleId><ArticleId IdType="pmc">PMC7355632</ArticleId><ArticleId IdType="pubmed">32560124</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian C.Q., Zhao K.J., Chen Y., Liu L., Liu X.D. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P-glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover. Eur. J. Pharm. Sci. 2019;134:194&#x2013;204. doi: 10.1016/j.ejps.2019.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2019.04.026</ArticleId><ArticleId IdType="pubmed">31047967</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezuruike U., Zhang M., Pansari A., De Sousa Mendes M., Pan X., Neuhoff S., Gardner I. Guide to development of compound files for PBPK modeling in the Simcyp population-based simulator. CPT Pharmacomet. Syst. Pharmacol. 2022;11:805&#x2013;821. doi: 10.1002/psp4.12791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psp4.12791</ArticleId><ArticleId IdType="pmc">PMC9286711</ArticleId><ArticleId IdType="pubmed">35344639</ArticleId></ArticleIdList></Reference><Reference><Citation>Shum S., Shen D.D., Isoherranen N. Predicting Maternal-Fetal Disposition of Fentanyl Following Intravenous and Epidural Administration Using Physiologically Based Pharmacokinetic Modeling. Drug Metab. Dispos. 2021;49:1003&#x2013;1015. doi: 10.1124/dmd.121.000612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.121.000612</ArticleId><ArticleId IdType="pmc">PMC11022861</ArticleId><ArticleId IdType="pubmed">34407992</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo H., Liu C., Li J., Zhang M., Hu M., Xu P., Liu L., Liu X. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions. J. Pharm. Sci. 2013;102:2819&#x2013;2836. doi: 10.1002/jps.23613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.23613</ArticleId><ArticleId IdType="pubmed">23760985</ArticleId></ArticleIdList></Reference><Reference><Citation>Obach R.S., Lombardo F., Waters N.J. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab. Dispos. 2008;36:1385&#x2013;1405. doi: 10.1124/dmd.108.020479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.108.020479</ArticleId><ArticleId IdType="pubmed">18426954</ArticleId></ArticleIdList></Reference><Reference><Citation>Baneyx G., Parrott N., Meille C., Iliadis A., Lave T. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: Influence of time between substrate and inducer administration. Eur. J. Pharm. Sci. 2014;56:1&#x2013;15. doi: 10.1016/j.ejps.2014.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2014.02.002</ArticleId><ArticleId IdType="pubmed">24530864</ArticleId></ArticleIdList></Reference><Reference><Citation>Yerasi N., Vurimindi H., Devarakonda K. Frog intestinal perfusion to evaluate drug permeability: Application to p-gp and cyp3a4 substrates. Front. Pharmacol. 2015;6:141. doi: 10.3389/fphar.2015.00141.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2015.00141</ArticleId><ArticleId IdType="pmc">PMC4500896</ArticleId><ArticleId IdType="pubmed">26236236</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H.Y., Chen X., Jiang J., Shi J., Hu P. Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration. Acta Pharmacol. Sin. 2016;37:276&#x2013;284. doi: 10.1038/aps.2015.122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aps.2015.122</ArticleId><ArticleId IdType="pmc">PMC4753367</ArticleId><ArticleId IdType="pubmed">26592516</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41390976</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-6535</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>Clinical pharmacology and therapeutics</Title><ISOAbbreviation>Clin Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Repeated Intake of Grapefruit Juice Inhibits CYP2B6, CYP2C9, CYP2C19, and CYP3A4 while Lingonberry Powder Does Not Induce Major CYP Enzymes in Humans.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpt.70165</ELocationID><Abstract><AbstractText>Grapefruit juice is a well-established inhibitor of cytochrome P450 (CYP) 3A4, but its effects on other CYP enzymes or organic anion transporting polypeptides (OATPs) are not fully characterized in humans. Recently, lingonberry powder was shown to induce murine CYP enzymes. We investigated the effects of lingonberry powder and grapefruit juice on seven CYP enzymes and two OATPs. Eleven healthy volunteers received three pretreatments three times per day: water for 1 day (control), lingonberry powder for 9&#x2009;days, and grapefruit juice for 3&#x2009;days. CYP index drugs (caffeine/CYP1A2, bupropion/CYP2B6, repaglinide/CYP2C8, flurbiprofen/CYP2C9, omeprazole/CYP2C19, dextromethorphan/CYP2D6, midazolam/CYP3A4, and simvastatin/CYP3A4) were administered orally on the study day of each pretreatment (day 1, 10, and 3, respectively). Venous blood samples were collected until 23&#x2009;hours postdose. The concentrations of index drugs, their metabolites and endogenous OATP1B1 and OATP1B3 biomarkers glycochenodeoxycholate 3-O-glucuronide (GCDCA-3G) and glycochenodeoxycholate 3-sulfate (GCDCA-3S), respectively, were quantified. Grapefruit juice expectedly increased the AUC<sub>0-23h</sub> values of the CYP3A4 index drugs midazolam and simvastatin (P&#x2009;&lt;&#x2009;0.01). Additionally, grapefruit juice decreased the hydroxybupropion/bupropion (CYP2B6), 4'-hydroxyflurbiprofen/flurbiprofen (CYP2C9), 5'-hydroxyomeprazole/omeprazole (CYP2C19), and 1'-hydroxymidazolam/midazolam AUC<sub>0-23h</sub> ratios to 0.57-fold (90% confidence interval: 0.45-0.74), 0.78-fold (0.69-0.87), 0.43-fold (0.36-0.52), and 0.72-fold (0.63-0.84) of control, respectively (P&#x2009;&lt;&#x2009;0.01). Lingonberry pretreatment did not change any CYP indices. GCDCA-3G and GCDCA-3S concentrations were unaffected by grapefruit juice or lingonberry pretreatment. Collectively, our findings indicate that in addition to inhibiting CYP3A4, repeated grapefruit juice intake causes clinically relevant inhibition of CYP2B6, CYP2C9, and CYP2C19, revealing previously underappreciated interaction risks. Conversely, lingonberry powder is unlikely to induce CYP enzymes in humans.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Clinical Pharmacology &amp; Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aurinsalo</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1915-6227</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lapatto-Reiniluoto</LastName><ForeName>Outi</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-2463-1862</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HUS Pharmacy, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurkela</LastName><ForeName>Mika</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4153-4143</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neuvonen</LastName><ForeName>Mikko</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7627-1638</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moilanen</LastName><ForeName>Eeva</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-8577-0316</Identifier><AffiliationInfo><Affiliation>The Immunopharmacology Research Group, Faculty of Medicine and Health Technology, Tampere University, and Tampere University Hospital, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niemi</LastName><ForeName>Mikko</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4550-2189</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tornio</LastName><ForeName>Aleksi</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5713-5692</Identifier><AffiliationInfo><Affiliation>Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Clinical Pharmacology, Turku University Hospital, Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Backman</LastName><ForeName>Janne T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0002-9577-2788</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Ther</MedlineTA><NlmUniqueID>0372741</NlmUniqueID><ISSNLinking>0009-9236</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>14</Day><Hour>15</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>14</Day><Hour>15</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>14</Day><Hour>7</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41390976</ArticleId><ArticleId IdType="doi">10.1002/cpt.70165</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bailey, D.G., Malcolm, J., Arnold, O. &amp; Spence, J.D. Grapefruit juice&#x2010;drug interactions. Br. J. Clin. Pharmacol. 58, 831&#x2013;843 (2004).</Citation></Reference><Reference><Citation>Lown, K.S. et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 99, 2545&#x2013;2553 (1997).</Citation></Reference><Reference><Citation>Bailey, D.G. Fruit juice inhibition of uptake transport: a new type of food&#x2010;drug interaction. Br. J. Clin. Pharmacol. 70, 645&#x2013;655 (2010).</Citation></Reference><Reference><Citation>Holmberg, M.T., Tornio, A., Neuvonen, M., Neuvonen, P.J., Backman, J.T. &amp; Niemi, M. Grapefruit juice inhibits the metabolic activation of clopidogrel. Clin. Pharmacol. Ther. 95, 307&#x2013;313 (2014).</Citation></Reference><Reference><Citation>Hulot, J.S. et al. Cytochrome P450 2C19 loss&#x2010;of&#x2010;function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108, 2244&#x2013;2247 (2006).</Citation></Reference><Reference><Citation>Ueda, N. et al. Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers. World J. Biol. Psychiatry 10, 832&#x2013;835 (2009).</Citation></Reference><Reference><Citation>Lee, A.J., Chan, W.K., Harralson, A.F., Buffum, J. &amp; Bui, B.C. The effects of grapefruit juice on sertraline metabolism: an in&#xa0;vitro and in&#xa0;vivo study. Clin. Ther. 21, 1890&#x2013;1899 (1999).</Citation></Reference><Reference><Citation>Ryyti, R., Hamalainen, M., Peltola, R. &amp; Moilanen, E. Beneficial effects of lingonberry (Vaccinium vitis&#x2010;idaea L.) supplementation on metabolic and inflammatory adverse effects induced by high&#x2010;fat diet in a mouse model of obesity. PLoS One 15, e0232605 (2020).</Citation></Reference><Reference><Citation>Ryyti, R., Pemmari, A., Peltola, R., Hamalainen, M. &amp; Moilanen, E. Effects of lingonberry (Vaccinium vitis&#x2010;idaea L.) supplementation on hepatic gene expression in high&#x2010;fat diet fed mice. Nutrients 13, 3693 (2021).</Citation></Reference><Reference><Citation>Aurinsalo, L. et al. A phenotyping tool for seven cytochrome P450 enzymes and two transporters: application to examine the effects of clopidogrel and gemfibrozil. Clin. Pharmacol. Ther. 117, 1732&#x2013;1742 (2025).</Citation></Reference><Reference><Citation>Lilja, J.J., Neuvonen, M. &amp; Neuvonen, P.J. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br. J. Clin. Pharmacol. 58, 56&#x2013;60 (2004).</Citation></Reference><Reference><Citation>Lilja, J.J., Kivisto, K.T. &amp; Neuvonen, P.J. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin. Pharmacol. Ther. 68, 384&#x2013;390 (2000).</Citation></Reference><Reference><Citation>Lilja, J.J., Kivisto, K.T. &amp; Neuvonen, P.J. Grapefruit juice&#x2010;simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG&#x2010;CoA reductase inhibitors. Clin. Pharmacol. Ther. 64, 477&#x2013;483 (1998).</Citation></Reference><Reference><Citation>Litonius, K. et al. Value of pharmacogenetic testing assessed with real&#x2010;world drug utilization and genotype data. Clin. Pharmacol. Ther. 117, 278&#x2013;288 (2025).</Citation></Reference><Reference><Citation>Wenzel, C., Lapczuk&#x2010;Romanska, J., Malinowski, D., Ostrowski, M., Drozdzik, M. &amp; Oswald, S. Comparative intra&#x2010;subject analysis of gene expression and protein abundance of major and minor drug metabolizing enzymes in healthy human jejunum and liver. Clin. Pharmacol. Ther. 115, 221&#x2013;230 (2024).</Citation></Reference><Reference><Citation>Lin, H.L., Kent, U.M. &amp; Hollenberg, P.F. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin&#x2010;dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J. Pharmacol. Exp. Ther. 313, 154&#x2013;164 (2005).</Citation></Reference><Reference><Citation>Lu, W.J., Ferlito, V., Xu, C., Flockhart, D.A. &amp; Caccamese, S. Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms. Chirality 23, 891&#x2013;896 (2011).</Citation></Reference><Reference><Citation>Tassaneeyakul, W., Guo, L.Q., Fukuda, K., Ohta, T. &amp; Yamazoe, Y. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch. Biochem. Biophys. 378, 356&#x2013;363 (2000).</Citation></Reference><Reference><Citation>Liu, Y. et al. Mechanistic study of bergamottin&#x2010;induced inactivation of CYP2C9. Food Chem. Toxicol. 153, 112278 (2021).</Citation></Reference><Reference><Citation>Seki, H., Akiyoshi, T., Imaoka, A. &amp; Ohtani, H. Inhibitory kinetics of fruit components on CYP2C19 activity. Drug Metab. Pharmacokinet. 34, 181&#x2013;186 (2019).</Citation></Reference><Reference><Citation>Wang, J.H. et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin. Pharmacol. Ther. 70, 42&#x2013;47 (2001).</Citation></Reference><Reference><Citation>Saiz&#x2010;Rodriguez, M. et al. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics and safety of sertraline in healthy volunteers. Basic Clin. Pharmacol. Toxicol. 122, 501&#x2013;511 (2018).</Citation></Reference><Reference><Citation>Hagelberg, N.M. et al. Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S&#x2010;ketamine. Eur. J. Pain 14, 625&#x2013;629 (2010).</Citation></Reference><Reference><Citation>Peltoniemi, M.A., Saari, T.I., Hagelberg, N.M., Laine, K., Neuvonen, P.J. &amp; Olkkola, K.T. S&#x2010;ketamine concentrations are greatly increased by grapefruit juice. Eur. J. Clin. Pharmacol. 68, 979&#x2013;986 (2012).</Citation></Reference><Reference><Citation>Peltoniemi, M.A. et al. Exposure to oral S&#x2010;ketamine is unaffected by itraconazole but greatly increased by ticlopidine. Clin. Pharmacol. Ther. 90, 296&#x2013;302 (2011).</Citation></Reference><Reference><Citation>Kazui, M. et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos. 38, 92&#x2013;99 (2010).</Citation></Reference><Reference><Citation>Damkier, P., Hansen, L.L. &amp; Br&#xf8;sen, K. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br. J. Clin. Pharmacol. 48, 829&#x2013;838 (1999).</Citation></Reference><Reference><Citation>Lilja, J.J., Niemi, M., Fredrikson, H. &amp; Neuvonen, P.J. Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br. J. Clin. Pharmacol. 63, 732&#x2013;740 (2007).</Citation></Reference><Reference><Citation>Kashihara, Y. et al. Small&#x2010;dosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1 and ABCG2), and interaction (atorvastatin and grapefruit juice) profiles of 5 probes for OATP2B1 and BCRP. J. Pharm. Sci. 106, 2688&#x2013;2694 (2017).</Citation></Reference><Reference><Citation>Girennavar, B., Jayaprakasha, G.K. &amp; Patil, B.S. Potent inhibition of human cytochrome P450 3A4, 2D6, and 2C9 isoenzymes by grapefruit juice and its furocoumarins. J. Food Sci. 72, C417&#x2013;C421 (2007).</Citation></Reference><Reference><Citation>Zhang, M. et al. Distribution characteristics and impacting factors of drug CYP enzymes and transporters in the gastrointestinal tract of Chinese healthy subjects. Clin. Pharmacol. Ther. 117, 676&#x2013;689 (2025).</Citation></Reference><Reference><Citation>Fuhr, U., Klittich, K. &amp; Staib, A.H. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br. J. Clin. Pharmacol. 35, 431&#x2013;436 (1993).</Citation></Reference><Reference><Citation>Maish, W.A., Hampton, E.M., Whitsett, T.L., Shepard, J.D. &amp; Lovallo, W.R. Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics. Pharmacotherapy 16, 1046&#x2013;1052 (1996).</Citation></Reference><Reference><Citation>Lane, H.Y. et al. Repeated ingestion of grapefruit juice does not alter clozapine&#x2019;s steady&#x2010;state plasma levels, effectiveness, and tolerability. J. Clin. Psychiatry 62, 812&#x2013;817 (2001).</Citation></Reference><Reference><Citation>Theile, D. et al. Clementine juice has the potential for drug interactions &#x2010; in&#xa0;vitro comparison with grapefruit and mandarin juice. Eur. J. Pharm. Sci. 97, 247&#x2013;256 (2017).</Citation></Reference><Reference><Citation>Bidstrup, T.B., Damkier, P., Olsen, A.K., Ekblom, M., Karlsson, A. &amp; Brosen, K. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide. Br. J. Clin. Pharmacol. 61, 49&#x2013;57 (2006).</Citation></Reference><Reference><Citation>Di Marco, M.P., Edwards, D.J., Wainer, I.W. &amp; Ducharme, M.P. The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P&#x2010;glycoprotein. Life Sci. 71, 1149&#x2013;1160 (2002).</Citation></Reference><Reference><Citation>Strauch, K., Lutz, U., Bittner, N. &amp; Lutz, W.K. Dose&#x2010;response relationship for the pharmacokinetic interaction of grapefruit juice with dextromethorphan investigated by human urinary metabolite profiles. Food Chem. Toxicol. 47, 1928&#x2013;1935 (2009).</Citation></Reference><Reference><Citation>Ducharme, J., Abdullah, S. &amp; Wainer, I.W. Dextromethorphan as an in&#xa0;vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J. Chromatogr. B Biomed. Appl. 678, 113&#x2013;128 (1996).</Citation></Reference><Reference><Citation>Kiiski, J.I. et al. Solanidine is a sensitive and specific dietary biomarker for CYP2D6 activity. Hum. Genomics 18, 11 (2024).</Citation></Reference><Reference><Citation>Lilja, J.J., Kivist&#xf6;, K.T., Backman, J.T. &amp; Neuvonen, P.J. Effect of grapefruit juice dose on grapefruit juice&#x2010;triazolam interaction: repeated consumption prolongs triazolam half&#x2010;life. Eur. J. Clin. Pharmacol. 56, 411&#x2013;415 (2000).</Citation></Reference><Reference><Citation>Park, S.J. et al. Pomegranate juice does not affect the disposition of simvastatin in healthy subjects. Eur. J. Drug Metab. Pharmacokinet. 41, 339&#x2013;344 (2016).</Citation></Reference><Reference><Citation>Greenblatt, D.J. et al. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin. Pharmacol. Ther. 74, 121&#x2013;129 (2003).</Citation></Reference><Reference><Citation>Kupferschmidt, H.H., Ha, H.R., Ziegler, W.H., Meier, P.J. &amp; Krahenbuhl, S. Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther. 58, 20&#x2013;28 (1995).</Citation></Reference><Reference><Citation>Farkas, D. et al. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450&#x2010;3A activity: comparison with grapefruit juice. J. Clin. Pharmacol. 47, 286&#x2013;294 (2007).</Citation></Reference><Reference><Citation>Veronese, M.L. et al. Exposure&#x2010;dependent inhibition of intestinal and hepatic CYP3A4 in&#xa0;vivo by grapefruit juice. J. Clin. Pharmacol. 43, 831&#x2013;839 (2003).</Citation></Reference><Reference><Citation>Paine, M.F. et al. A furanocoumarin&#x2010;free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice&#x2010;felodipine interaction. Am. J. Clin. Nutr. 83, 1097&#x2013;1105 (2006).</Citation></Reference><Reference><Citation>Takumi, S. et al. Naringin attenuates the cytotoxicity of hepatotoxin microcystin&#x2010;LR by the curious mechanisms to OATP1B1&#x2010; and OATP1B3&#x2010;expressing cells. Environ. Toxicol. Pharmacol. 39, 974&#x2013;981 (2015).</Citation></Reference><Reference><Citation>Mandery, K., Balk, B., Bujok, K., Schmidt, I., Fromm, M.F. &amp; Glaeser, H. Inhibition of hepatic uptake transporters by flavonoids. Eur. J. Pharm. Sci. 46, 79&#x2013;85 (2012).</Citation></Reference><Reference><Citation>Hu, M., Mak, V.W., Yin, O.Q., Chu, T.T. &amp; Tomlinson, B. Effects of grapefruit juice and SLCO1B1 388A&gt;G polymorphism on the pharmacokinetics of pitavastatin. Drug Metab. Pharmacokinet. 28, 104&#x2013;108 (2013).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">41274826</PMID><DateCompleted><Year>2026</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2026</Year><Month>01</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-114X</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Clinical therapeutics</Title><ISOAbbreviation>Clin Ther</ISOAbbreviation></Journal><ArticleTitle>Phase 1 Study Evaluating the Effect of Food and Omeprazole-Induced Gastric pH Change on the Pharmacokinetics and Safety of Imlunestrant in Healthy Females.</ArticleTitle><Pagination><StartPage>81</StartPage><EndPage>87</EndPage><MedlinePgn>81-87</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinthera.2025.10.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0149-2918(25)00368-6</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To assess the effect of low-fat food intake and the effect of a gastric acid reducing agent (omeprazole) on imlunestrant pharmacokinetics (PK), safety, and tolerability.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A phase 1, open-label cohort study (NCT04840888) in healthy adult females of non-childbearing potential Food effect was evaluated in cohort 1 in which, participants were randomized (1:1) to fasted/fed or fed/fasted crossover treatment sequences and received one dose of 400 mg imlunestrant once-daily in each fed (a low-fat meal; 500 calories, 13% fat) or fasted state with 4 days washout period between doses. Omeprazole's effect was evaluated in cohort 2, in which participants received imlunestrant in fixed treatment sequence with a washout period between doses: (1) a single dose of 400 mg imlunestrant alone on Day 1, (2) no treatment between Day 2-Day 5, (3) 40 mg omeprazole alone once-daily between Day 5-8, and (4) 400 mg imlunestrant + 40 mg omeprazole on Day 9. Blood samples for PK assessments were collected for the evaluation of the areas under the concentration curve AUC<sub>(0-96h)</sub>, AUC<sub>(0-&#x221e;)</sub>, maximum observed drug concentration (C<sub>max</sub>), time of maximum observed drug concentration (&#x3a4;<sub>max</sub>); their geometric least squares (GLS) mean ratios were calculated. Safety assessments involved monitoring of adverse events (AEs), clinical chemistry, hematology, vital signs, 12-lead electrocardiogram, and physical examination.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Eight females were enrolled in cohort 1 and 10 in cohort 2. In cohort 1, PK parameters were statistically significantly increased with GLS mean ratios (90% CI): 1.99 (1.67, 2.36) in AUC<sub>(0-96h)</sub>, 2.04 (1.41, 2.94) in AUC<sub>(0-&#x221e;)</sub>, and 3.55 (2.83, 4.45) in C<sub>max</sub>, following dosing with imlunestrant in the fed state compared to the fasted state. The change in &#x3a4;<sub>max</sub> was not statistically significant. In cohort 2, the change in PK parameters of imlunestrant when dosed alone and in the presence of the PPI omeprazole were not statistically significant and were comparable. Imlunestrant was well tolerated, and no clinically meaningful findings were recorded in either cohort.</AbstractText><AbstractText Label="IMPLICATIONS" NlmCategory="CONCLUSIONS">Low-fat food intake resulted in increases of &#x223c;2-fold in AUC and &#x223c;3.6-fold in C<sub>max</sub>. Therefore, patients will be instructed to abstain from food consumption two hours before and one hour after taking imlunestrant. Concomitant use of imlunestrant and omeprazole displayed a low risk of drug-drug interaction, therefore imlunestrant may be taken with a proton pump inhibitor such as omeprazole. A single oral dose of 400 mg imlunestrant was generally well tolerated in healthy females regardless of food or omeprazole intake.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Eli Lilly &amp; Company. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Datta-Mannan</LastName><ForeName>Amita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Lilly Corporate Center Indianapolis, Indianapolis, Indiana. Electronic address: datta_amita@lilly.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shanks</LastName><ForeName>Elaine</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, 8 Arlington Square West, Downshire Way, Bracknell, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuen</LastName><ForeName>Eunice</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, 8 Arlington Square West, Downshire Way, Bracknell, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Yingying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Lilly Corporate Center Indianapolis, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xuejing Aimee</ForeName><Initials>XA</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Lilly Corporate Center Indianapolis, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Ther</MedlineTA><NlmUniqueID>7706726</NlmUniqueID><ISSNLinking>0149-2918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>KG60484QX9</RegistryNumber><NameOfSubstance UI="D009853">Omeprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054328">Proton Pump Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009853" MajorTopicYN="Y">Omeprazole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018565" MajorTopicYN="Y">Food-Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054328" MajorTopicYN="Y">Proton Pump Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005215" MajorTopicYN="N">Fasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Drug-food interactions</Keyword><Keyword MajorTopicYN="N">Food effect</Keyword><Keyword MajorTopicYN="N">Imlunestrant</Keyword><Keyword MajorTopicYN="N">Omeprazole, Pharmacokinetics</Keyword><Keyword MajorTopicYN="N">Proton pump inhibitor</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Eunice Yuen reports a relationship with Eli Lilly and Company that includes: employment and equity or stocks. Yingying Guo reports a relationship with Eli Lilly and Company that includes: employment and equity or stocks. Elaine Shanks reports a relationship with Eli Lilly and Company that includes: employment and equity or stocks. Amita Datta-Mannan reports a relationship with Eli Lilly and Company that includes: employment and equity or stocks. Xuejing Aimee Wang reports a relationship with Eli Lilly and Company that includes: employment and equity or stocks.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>19</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>23</Day><Hour>0</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>22</Day><Hour>21</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41274826</ArticleId><ArticleId IdType="doi">10.1016/j.clinthera.2025.10.007</ArticleId><ArticleId IdType="pii">S0149-2918(25)00368-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40607942</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-4604</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>11</Issue><PubDate><Year>2025</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of clinical pharmacology</Title><ISOAbbreviation>J Clin Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Methoxyethyl Etomidate Hydrochloride (ET-26): A Phase I Clinical Trial Assessing Drug-Drug Interactions in Healthy Subjects.</ArticleTitle><Pagination><StartPage>1443</StartPage><EndPage>1450</EndPage><MedlinePgn>1443-1450</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jcph.70071</ELocationID><Abstract><AbstractText>Methoxyethyl etomidate hydrochloride (ET-26) is a novel intravenous general anesthetic designed to address the clinical limitations of etomidate. This Phase I clinical trial assessed the pharmacokinetics, pharmacodynamics, drug-drug interaction (DDI) potential, and safety of ET-26 in 68 healthy subjects across three sequences, evaluating interactions with rifampin (CYP2C19/3A4 inducer), fluconazole (CYP2C19/3A4 inhibitor), and omeprazole/midazolam. ET-26 pharmacokinetic analyses showed that compared with administration of ET-26 alone, co-administration of rifampin resulted in a 10% decrease in the geometric mean ratio (GMR) of the AUC<sub>0-&#x221e;</sub> for ET-26 (GMR 90.0%, 90% CI 85.4%-94.8%), while co-administration fluconazole increased the AUC<sub>0-&#x221e;</sub> by 18.5% (GMR 118.5%, 90% CI 111.4%-126.2%). ET-26 slightly increased the AUC<sub>0-&#x221e;</sub> by 18.5% for omeprazole (GMR 118.5%, 90% CI 111.4%-126.1%) and 11.1% for midazolam (GMR 111.1%, 90% CI 104.9%-117.8%). The 90% CI for key parameters largely fell within no-effect boundaries, indicating no clinically significant DDIs. Pharmacodynamic assessments showed consistent sedation profiles across sequences, with mild additive effects with midazolam. Safety evaluations identified treatment-emergent adverse events such as injection site pain and myoclonus, more frequent with fluconazole. No serious adverse events were observed. These findings suggest ET-26 exhibits a favorable safety and pharmacokinetic profile with no significant DDIs observed in clinical, supporting its potential as a safer alternative to etomidate for general anesthesia.</AbstractText><CopyrightInformation>&#xa9; 2025, The American College of Clinical Pharmacology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Institute of Clinical Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Pan-Pan</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Institute of Clinical Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Wen-Shuo</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Institute of Clinical Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Li-Ze</ForeName><Initials>LZ</Initials><AffiliationInfo><Affiliation>Avanc Pharmaceutical Co., Ltd., Jinzhou, Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Bao-Zhong</ForeName><Initials>BZ</Initials><AffiliationInfo><Affiliation>Avanc Pharmaceutical Co., Ltd., Jinzhou, Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van denAnker</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Institute of Clinical Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Children's National Hospital, Washington, DC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Pediatrics, Pharmacology &amp; Physiology, Genomics and Precision Medicine, School of Medicine and Health Sciences, George Washington University, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xin-Mei</ForeName><Initials>XM</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University &amp; Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Lin-Lin</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University &amp; Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiao-Ran</ForeName><Initials>XR</Initials><AffiliationInfo><Affiliation>Avanc Pharmaceutical Co., Ltd., Jinzhou, Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Institute of Clinical Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ke</LastName><ForeName>Bo-Wen</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Laboratory of Anesthesia and Critical Care Medicine, National-Local Joint Engineering Research Centre of Translational Medicine of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Wei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-1830-338X</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Institute of Clinical Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2023YFC2706100</GrantID><Agency>National Key R&amp;D Program of China</Agency><Country/></Grant><Grant><GrantID>82425054;82273784</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>NO.tstp20230660</GrantID><Agency>Taishan Scholar Project of Shandong Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Clin Pharmacol</MedlineTA><NlmUniqueID>0366372</NlmUniqueID><ISSNLinking>0091-2700</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018686">Anesthetics, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber><NameOfSubstance UI="C045793">CYP2C19 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber><NameOfSubstance UI="D065731">Cytochrome P-450 CYP2C19</NameOfSubstance></Chemical><Chemical><RegistryNumber>Z22628B598</RegistryNumber><NameOfSubstance UI="D005045">Etomidate</NameOfSubstance></Chemical><Chemical><RegistryNumber>8VZV102JFY</RegistryNumber><NameOfSubstance UI="D015725">Fluconazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>R60L0SM5BC</RegistryNumber><NameOfSubstance UI="D008874">Midazolam</NameOfSubstance></Chemical><Chemical><RegistryNumber>KG60484QX9</RegistryNumber><NameOfSubstance UI="D009853">Omeprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>VJT6J7R4TR</RegistryNumber><NameOfSubstance UI="D012293">Rifampin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018686" MajorTopicYN="Y">Anesthetics, Intravenous</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065731" MajorTopicYN="N">Cytochrome P-450 CYP2C19</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005045" MajorTopicYN="Y">Etomidate</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015725" MajorTopicYN="N">Fluconazole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008874" MajorTopicYN="N">Midazolam</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009853" MajorTopicYN="N">Omeprazole</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012293" MajorTopicYN="N">Rifampin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Phase 1 clinical trial</Keyword><Keyword MajorTopicYN="N">drug&#x2013;drug interaction</Keyword><Keyword MajorTopicYN="N">etomidate analogs</Keyword><Keyword MajorTopicYN="N">intravenous anesthetic</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>27</Day><Hour>13</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>3</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>3</Day><Hour>10</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40607942</ArticleId><ArticleId IdType="doi">10.1002/jcph.70071</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Erdoes G, Basciani RM, Eberle B. Etomidate&#x2013;a review of robust evidence for its use in various clinical scenarios. Acta Anaesthesiol Scand. 2014;58(4):380&#x2010;389.</Citation></Reference><Reference><Citation>Kochs E, Treede RD, Schulte am Esch J. Increase in somatosensory evoked potentials during anesthesia induction with etomidate. Anaesthesist. 1986;35(6):359&#x2010;364.</Citation></Reference><Reference><Citation>Zhang YJ, Jiang YY, Chang P, et&#xa0;al. Safety pharmacology study of ET&#x2010;26 hydrochloride, a potential drug for intravenous general anesthesia, in rats and beagle dogs. Front Pharmacol. 2021;12:679381.</Citation></Reference><Reference><Citation>Wang B, Yang J, Chen J, et&#xa0;al. An etomidate analogue with less adrenocortical suppression, stable hemodynamics, and improved behavioral recovery in rats. Anesth Analg. 2017;125(2):442&#x2010;450.</Citation></Reference><Reference><Citation>Liu X, Song H, Yang J, et&#xa0;al. The etomidate analog ET&#x2010;26 HCl retains superior myocardial performance: comparisons with etomidate in vivo and in vitro. PLOS ONE. 2018;13(1):e0190994.</Citation></Reference><Reference><Citation>Yang J, Kang Y, Wang B, Yang L, Liu J, Zhang W. Metabolite&#x2010;inactive etomidate analogues alleviating suppression on adrenal function in Beagle dogs. Eur J Pharm Sci. 2017;99:343&#x2010;349.</Citation></Reference><Reference><Citation>Yin Q, Yang Y, Liu J, et&#xa0;al. Phase 1 single&#x2010;centre placebo&#x2010; and etomidate&#x2010;controlled study in healthy volunteers to assess safety, tolerability, clinical effects, and pharmacokinetics of intravenous methoxyethyl etomidate hydrochloride (ET&#x2010;26). Br J Anaesth. 2025;134(1):80&#x2010;88.</Citation></Reference><Reference><Citation>Zhang YJ, Deng CY, Yang J, et&#xa0;al. Preclinical pharmacokinetics study of a novel intravenous anesthetic ET&#x2010;26 hydrochloride. Curr Drug Metab. 2019;20(13):1073&#x2010;1081.</Citation></Reference><Reference><Citation>Das S, Behera SK, Xavier AS, Dharanipragada S, Selvarajan S. Are drug&#x2010;drug interactions a real clinical concern? Perspect Clin Res. 2019;10(2):62&#x2010;66.</Citation></Reference><Reference><Citation>Ribeiro MR, Motta AA, Marcondes&#x2010;Fonseca LA, Kalil&#x2010;Filho J, Giavina&#x2010;Bianchi P. Increase of 10% in the rate of adverse drug reactions for each drug administered in hospitalized patients. Clinics. 2018;73:1&#x2010;7.</Citation></Reference><Reference><Citation>van den Berg JP, Vereecke HE, Proost JH, et&#xa0;al. Pharmacokinetic and pharmacodynamic interactions in anaesthesia. A review of current knowledge and how it can be used to optimize anaesthetic drug administration. Br J Anaesth. 2017;118(1):44&#x2010;57.</Citation></Reference><Reference><Citation>(CDE) TCfDE. Technical Guidelines for Clinical Evaluation of Intravenous General Anesthetics. CDE; 2022.</Citation></Reference><Reference><Citation>Patel HH, Pearn ML, Patel PM, Roth DM. General anesthetics and therapeutic aases. In: Brunton LL, Hilal&#x2010;Dandan R, Knollmann BC, eds. Goodman &amp; Gilman's: The Pharmacological Basis of Therapeutics, 13 ed. McGraw&#x2010;Hill Education; 2017.</Citation></Reference><Reference><Citation>Ackerman RS, Luddy KA, Icard BE, Pi&#xf1;eiro Fern&#xe1;ndez J, Gatenby RA, Muncey AR. The effects of anesthetics and perioperative medications on immune function: a narrative review. Anesth Analg. 2021;133(3):676&#x2010;689.</Citation></Reference><Reference><Citation>Zhang G&#x2010;H, Sun L. Peri&#x2010;intubation hemodynamic changes during low dose fentanyl, remifentanil and sufentanil combined with etomidate for anesthetic induction. Chin Med J. 2009;122(19):2330&#x2010;2334.</Citation></Reference><Reference><Citation>Jiang Z, Xiao J, Wang X, Luo T. The effect&#x2010;site concentration of remifentanil blunting endotracheal intubation responses during anesthesia induction with etomidate: a dose&#x2010;finding study. BMC Anesthesiol. 2023;23(1):225.</Citation></Reference><Reference><Citation>Isitemiz I, Uzman S, Topta&#x15f; M, et&#xa0;al. Prevention of etomidate&#x2010;induced myoclonus: which is superior: fentanyl, midazolam, or a combination? A retrospective comparative study. Med Sci Monit. 2014;20:262&#x2010;267.</Citation></Reference><Reference><Citation>Silva A, Costa B, Castro I, Mour&#xe3;o J, Vale N. New perspective for drug&#x2013;drug interaction in perioperative period. J Clin Med. 2023;12(14):4810.</Citation></Reference><Reference><Citation>Mohsen S, Dickinson JA, Somayaji R. Update on the adverse effects of antimicrobial therapies in community practice. Can Fam Physician. 2020;66(9):651&#x2010;659.</Citation></Reference><Reference><Citation>Kim JH, Byun S, Choi YJ, et&#xa0;al. Efficacy and safety of etomidate in comparison with propofol or midazolam as sedative for upper gastrointestinal endoscopy. Clin Endosc. 2020;53(5):555&#x2010;561.</Citation></Reference><Reference><Citation>Salim B, Siddiqui S, Shamim F, Haider S. Effectiveness of midazolam in the prevention of etomidate induced myoclonus. J Anesth Clin Res. 2015;6(2):503&#x2010;505.</Citation></Reference><Reference><Citation>Inomata S, Nagashima A, Itagaki F, et&#xa0;al. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther. 2005;78(6):647&#x2010;655.</Citation></Reference><Reference><Citation>Mikstacki A, Skrzypczak&#x2010;Zielinska M, Tamowicz B, Zakerska&#x2010;Banaszak O, Szalata M, Slomski R. The impact of genetic factors on response to anaesthetics. Adv Med Sci. 2013;58(1):9&#x2010;14.</Citation></Reference><Reference><Citation>Spriet I, Meersseman W, de Hoon J, von Winckelmann S, Wilmer A, Willems L. Mini&#x2010;series: II. Clinical aspects. Clinically relevant CYP450&#x2010;mediated drug interactions in the ICU. Intensive Care Med. 2009;35(4):603&#x2010;612.</Citation></Reference><Reference><Citation>Forman SA, Warner DS. Clinical and molecular pharmacology of etomidate. Anesthesiology. 2011;114(3):695&#x2010;707.</Citation></Reference><Reference><Citation>Valk BI, Struys MMRF. Etomidate and its analogs: a review of pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2021;60(10):1253&#x2010;1269.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40324687</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-6017</ISSN><JournalIssue CitedMedium="Internet"><Volume>114</Volume><Issue>12</Issue><PubDate><Year>2025</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of pharmaceutical sciences</Title><ISOAbbreviation>J Pharm Sci</ISOAbbreviation></Journal><ArticleTitle>Vitamin C reduces gastric pH in pharmacologically induced hypochlorhydria: A potential approach for mitigating pH-dependent drug-drug interactions of weak-base drugs.</ArticleTitle><Pagination><StartPage>103809</StartPage><MedlinePgn>103809</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xphs.2025.103809</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-3549(25)00266-7</ELocationID><Abstract><AbstractText>Orally administered, poorly soluble, weak-base drugs are subject to gastric pH-dependent drug-drug interactions which can be clinically significant. Proton pump inhibitors (PPIs) have been shown to reduce the bioavailability of kinase inhibitors, antivirals and triazole antifungals, through elevation of gastric pH. The objective of this study was to determine if chewable ascorbic acid (AA) tablets can induce a transient reduction in gastric pH. Healthy volunteers were pretreated with 20 mg omeprazole to induce hypochlorhydria. On the study day, gastric pH was continuously monitored using a catheter-based pH monitoring system. A pH electrode was transnasally placed in the stomach fundus and pH data was collected in real time. 1000 mg AA chewable tablets were ingested by the study participants with 240 mL of water. In five out of six subjects, a significant drop in gastric pH was observed. A mean (&#xb1; SD) drop in pH of 3.7 (&#xb1; 1.8) upon AA intake was observed and time taken to reach lowest gastric pH was 91.2 (&#xb1; 64) min. Area under the pH versus time curve (AUC<sub>pH</sub>), below median pH over 15 min duration before AA intake, was determined to be 186.8 &#xb1; 136.7 (&#x394;pH.min). This pilot study demonstrates that 1000 mg of AA tablets can significantly reduce gastric pH in individuals receiving treatment with PPIs, providing a potential approach for mitigating pH-dependent drug-drug interactions of weak-base drugs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fadda</LastName><ForeName>Hala M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy &amp; Health Sciences, Butler University, IN, United States. Electronic address: hfadda@butler.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Indiana University Division of Gastroenterology and Hepatology, Indianapolis, IN, United States; Vatche and Tamar Manoukian Division of Digestive Diseases at the University of California Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waseem</LastName><ForeName>Mohammed Rayyan</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Indiana University Division of Gastroenterology and Hepatology, Indianapolis, IN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camilleri</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Pharm Sci</MedlineTA><NlmUniqueID>2985195R</NlmUniqueID><ISSNLinking>0022-3549</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>PQ6CK8PD0R</RegistryNumber><NameOfSubstance UI="D001205">Ascorbic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054328">Proton Pump Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>KG60484QX9</RegistryNumber><NameOfSubstance UI="D009853">Omeprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013607">Tablets</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001205" MajorTopicYN="Y">Ascorbic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054328" MajorTopicYN="N">Proton Pump Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000126" MajorTopicYN="Y">Achlorhydria</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009853" MajorTopicYN="N">Omeprazole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005753" MajorTopicYN="N">Gastric Mucosa</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Absorption</Keyword><Keyword MajorTopicYN="N">Controlled release</Keyword><Keyword MajorTopicYN="N">Drug-drug interaction(s)</Keyword><Keyword MajorTopicYN="N">Duodenum</Keyword><Keyword MajorTopicYN="N">Gastrointestinal tract</Keyword><Keyword MajorTopicYN="N">Geriatric</Keyword><Keyword MajorTopicYN="N">Physicochemical properties</Keyword><Keyword MajorTopicYN="N">Solubility</Keyword><Keyword MajorTopicYN="N">Transit time (s)</Keyword><Keyword MajorTopicYN="N">pH</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>26</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>6</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>5</Day><Hour>19</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40324687</ArticleId><ArticleId IdType="doi">10.1016/j.xphs.2025.103809</ArticleId><ArticleId IdType="pii">S0022-3549(25)00266-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40264660</PMID><DateRevised><Year>2025</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle><i>In vivo</i> effects of bempedoic acid on microdosed CYP probe drugs.</ArticleTitle><Pagination><StartPage>1544956</StartPage><MedlinePgn>1544956</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1544956</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2025.1544956</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Bempedoic acid (BA) is a novel oral cholesterol-lowering drug. So far, <i>in vivo</i> evidence on potential drug-drug interactions via the cytochrome P450 (CYP) enzymes is lacking.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In a clinical trial, we evaluated the effect of BA on microdosed probe drugs using a limited sampling strategy in healthy volunteers. The outcome measures were as follows: 1) the omeprazole AUC<sub>0-4h</sub> and hydroxylation index (HI) after a 100&#xa0;&#xb5;g dose to evaluate CYP2C19 activity, 2) the midazolam AUC<sub>2-4h</sub> after a 30&#xa0;&#xb5;g dose to evaluate CYP3A activity, and 3) the yohimbine AUC<sub>0-4h</sub> after a 50&#xa0;&#xb5;g dose to evaluate CYP2D6 activity. Partial areas under the curve (AUCs) were evaluated at baseline and under BA steady state. The endpoints were the geometric mean ratios (GMRs) with 95% confidence intervals (CI) of the partial AUCs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In 15 participants, the AUC<sub>0-4h</sub> of omeprazole and its HI significantly decreased (GMR: 0.75, 90% CI: 0.66-0.85; change in HI <i>p</i> &lt; 0.0001). There was no change in the AUC<sub>2-4h</sub> of midazolam (GMR: 1.18, 90% CI: 0.87-1.61) and AUC<sub>0-4h</sub> of yohimbine (GMR: 0.92, 90% CI: 0.75-1.14).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">In healthy volunteers, BA was a mild inducer of CYP2C19 and did not affect CYP3A or CYP2D6 activity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Stoll, Amato, Burhenne and Blank.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stoll</LastName><ForeName>Felicitas</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Internal Medicine IX - Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Medical Faculty Heidelberg/Heidelberg University Hospital, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amato</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Internal Medicine IX - Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Medical Faculty Heidelberg/Heidelberg University Hospital, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burhenne</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Internal Medicine IX - Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Medical Faculty Heidelberg/Heidelberg University Hospital, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blank</LastName><ForeName>Antje</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Internal Medicine IX - Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Medical Faculty Heidelberg/Heidelberg University Hospital, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CYP2C19</Keyword><Keyword MajorTopicYN="N">CYP2D6</Keyword><Keyword MajorTopicYN="N">CYP3A</Keyword><Keyword MajorTopicYN="N">bempedoic acid</Keyword><Keyword MajorTopicYN="N">limited sampling strategy</Keyword><Keyword MajorTopicYN="N">microdosed probe drugs</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>23</Day><Hour>4</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40264660</ArticleId><ArticleId IdType="pmc">PMC12012300</ArticleId><ArticleId IdType="doi">10.3389/fphar.2025.1544956</ArticleId><ArticleId IdType="pii">1544956</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amore B. M., Cramer C., MacDougall D., Emery M. G. (2023). The disposition and metabolism of bempedoic acid, a potent inhibitor of ATP citrate lyase, in healthy human subjects. Drug Metab. Dispos. 51 (5), 599&#x2013;609. 10.1124/dmd.122.001142</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.122.001142</ArticleId><ArticleId IdType="pubmed">36878717</ArticleId></ArticleIdList></Reference><Reference><Citation>Asiimwe I. G., Pirmohamed M. (2022). Drug-drug-gene interactions in cardiovascular medicine. Pharmgenomics Pers. Med. 15, 879&#x2013;911. 10.2147/PGPM.S338601</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/PGPM.S338601</ArticleId><ArticleId IdType="pmc">PMC9639705</ArticleId><ArticleId IdType="pubmed">36353710</ArticleId></ArticleIdList></Reference><Reference><Citation>Burhenne J., Halama B., Maurer M., Riedel K. D., Hohmann N., Mikus G., et al. (2012). Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1'-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry. Anal. Bioanal. Chem. 402 (7), 2439&#x2013;2450. 10.1007/s00216-011-5675-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00216-011-5675-y</ArticleId><ArticleId IdType="pubmed">22252655</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicero A. F. G., Fogacci F., Cincione I. (2021). Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia. Expert Opin. Drug Metab. Toxicol. 17 (9), 1031&#x2013;1038. 10.1080/17425255.2021.1951222</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17425255.2021.1951222</ArticleId><ArticleId IdType="pubmed">34197267</ArticleId></ArticleIdList></Reference><Reference><Citation>Corn G., Lund M., Andersson N. W., Dohlmann T. L., Hlatky M. A., Wohlfahrt J., et al. (2024). Low-density lipoprotein cholesterol response to statins according to comorbidities and co-medications: a population-based study. Am. Heart J. 274, 102&#x2013;112. 10.1016/j.ahj.2024.04.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2024.04.018</ArticleId><ArticleId IdType="pubmed">38710378</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbe A., Foerster K. I., Blank A., Rose P., Burhenne J., Haefeli W. E., et al. (2022). Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. Eur. J. Clin. Pharmacol. 78 (6), 975&#x2013;987. 10.1007/s00228-022-03304-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-022-03304-3</ArticleId><ArticleId IdType="pmc">PMC9107402</ArticleId><ArticleId IdType="pubmed">35238961</ArticleId></ArticleIdList></Reference><Reference><Citation>EMA, (2024). Nilemdo Summary of Product Characteristics. Daiichi Sankyo europe GmbH.</Citation></Reference><Reference><Citation>EMA, (2020). Nustendi Summary of Product Characteristics. Daiichi Sankyo europe GmbH.</Citation></Reference><Reference><Citation>FDA (2019). Integrated Review NDA211616 Nexletol (bempedoic acid) tablets</Citation></Reference><Reference><Citation>
FDA (2024). FDA&#x2019;s examples of drugs that interact with CYP enzymes and transporter systems. Available online at: https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems. (Accessed February 21, 2025)
</Citation></Reference><Reference><Citation>Halama B., Hohmann N., Burhenne J., Weiss J., Mikus G., Haefeli W. E. (2013). A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin. Pharmacol. Ther. 93 (6), 564&#x2013;571. 10.1038/clpt.2013.27</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2013.27</ArticleId><ArticleId IdType="pubmed">23511711</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiemke C., Bergemann N., Clement H. W., Conca A., Deckert J., Domschke K., et al. (2018). Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51 (1-02), e1. 10.1055/s-0037-1600991</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1600991</ArticleId><ArticleId IdType="pubmed">29390205</ArticleId></ArticleIdList></Reference><Reference><Citation>ICH (2022). Bioanalytical method validation and sample analysis M10</Citation></Reference><Reference><Citation>Katzenmaier S., Markert C., Mikus G. (2010). Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam. Eur. J. Clin. Pharmacol. 66 (11), 1137&#x2013;1141. 10.1007/s00228-010-0878-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-010-0878-2</ArticleId><ArticleId IdType="pubmed">20680253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoudi M., Foerster K. I., Burhenne J., Weiss J., Mikus G., Haefeli W. E. (2021). Application of microdosed intravenous omeprazole to determine hepatic CYP2C19 activity. J. Clin. Pharmacol. 61 (6), 789&#x2013;798. 10.1002/jcph.1789</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.1789</ArticleId><ArticleId IdType="pubmed">33236774</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhareb A., Blank A., Meid A. D., Foerster K. I., Stoll F., Burhenne J., et al. (2023). CYP3A and CYP2C19 activity determined by microdosed probe drugs accurately predict voriconazole clearance in healthy adults. Clin. Pharmacokinet. 62 (9), 1305&#x2013;1314. 10.1007/s40262-023-01287-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-023-01287-7</ArticleId><ArticleId IdType="pmc">PMC10450012</ArticleId><ArticleId IdType="pubmed">37505445</ArticleId></ArticleIdList></Reference><Reference><Citation>Nissen S. E., Lincoff A. M., Brennan D., Ray K. K., Mason D., Kastelein J. J. P., et al. (2023). Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N. Engl. J. Med. 388 (15), 1353&#x2013;1364. 10.1056/NEJMoa2215024</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2215024</ArticleId><ArticleId IdType="pubmed">36876740</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray K. K., Bays H. E., Catapano A. L., Lalwani N. D., Bloedon L. T., Sterling L. R., et al. (2019). Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N. Engl. J. Med. 380 (11), 1022&#x2013;1032. 10.1056/NEJMoa1803917</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1803917</ArticleId><ArticleId IdType="pubmed">30865796</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohr B. S., Krohmer E., Foerster K. I., Burhenne J., Schulz M., Blank A., et al. (2024). Time course of the interaction between oral short-term ritonavir therapy with three factor xa inhibitors and the activity of CYP2D6, CYP2C19, and CYP3A4 in healthy volunteers. Clin. Pharmacokinet. 63 (4), 469&#x2013;481. 10.1007/s40262-024-01350-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-024-01350-x</ArticleId><ArticleId IdType="pmc">PMC11052790</ArticleId><ArticleId IdType="pubmed">38393578</ArticleId></ArticleIdList></Reference><Reference><Citation>SmPC (2022). &#x201c;Plavix&#xae; 75 mg Filmtabletten,&#x201d; Sanofi-aventis Deutschland.</Citation></Reference><Reference><Citation>Stoll F., Amato S., Sauter M., Burhenne J., Weiss J., Haefeli W. E., et al. (2025). Effect of staggered vs. Simultaneous Co-administration of bempedoic acid on pharmacokinetics of pravastatin: randomized, cross-over clinical trial in healthy volunteers. Pharmaceutics 17 (1), 60. 10.3390/pharmaceutics17010060</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics17010060</ArticleId><ArticleId IdType="pmc">PMC11768435</ArticleId><ArticleId IdType="pubmed">39861708</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoll F., Blank A., Mikus G., Czock D., Weiss J., Meyer-T&#xf6;nnies M. J., et al. (2024). Evaluation of hydroxychloroquine as a perpetrator on cytochrome P450 (CYP) 3A and CYP2D6 activity with microdosed probe drugs in healthy volunteers. Eur. J. Drug Metab. Pharmacokinet. 49 (1), 101&#x2013;109. 10.1007/s13318-023-00872-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13318-023-00872-2</ArticleId><ArticleId IdType="pmc">PMC10781839</ArticleId><ArticleId IdType="pubmed">38114885</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoll F., Eidam A., Michael L., Bauer J. M., Haefeli W. E. (2022). Drug treatment of hypercholesterolemia in older adults: focus on newer agents. Drugs Aging 39 (4), 251&#x2013;256. 10.1007/s40266-022-00928-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40266-022-00928-z</ArticleId><ArticleId IdType="pmc">PMC8995260</ArticleId><ArticleId IdType="pubmed">35278206</ArticleId></ArticleIdList></Reference><Reference><Citation>
van der Heijden L. T., Opdam F. L., Beijnen J. H., Huitema A. D. R. (2024). The use of microdosing for <i>in vivo</i> phenotyping of cytochrome P450 enzymes: where do we stand? A narrative review. Eur. J. Drug Metab. Pharmacokinet.
49 (4), 407&#x2013;418. 10.1007/s13318-024-00896-2

</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13318-024-00896-2</ArticleId><ArticleId IdType="pmc">PMC11199305</ArticleId><ArticleId IdType="pubmed">38689161</ArticleId></ArticleIdList></Reference><Reference><Citation>Vay M., Meyer M. J., Blank A., Skopp G., Rose P., Tzvetkov M. V., et al. (2020). Oral yohimbine as a new probe drug to predict CYP2D6 activity: results of a fixed-sequence phase I trial. Clin. Pharmacokinet. 59 (7), 927&#x2013;939. 10.1007/s40262-020-00862-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-020-00862-6</ArticleId><ArticleId IdType="pmc">PMC7329762</ArticleId><ArticleId IdType="pubmed">32060866</ArticleId></ArticleIdList></Reference><Reference><Citation>Vay M., Sauter M., Mikus G., Burhenne J. (2019). Quantification of microdosed oral yohimbine and its major metabolite in human plasma in the picogram range. Bioanalysis 11 (16), 1459&#x2013;1467. 10.4155/bio-2019-0129</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/bio-2019-0129</ArticleId><ArticleId IdType="pubmed">31411489</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39982209</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-6535</ISSN><JournalIssue CitedMedium="Internet"><Volume>117</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Clinical pharmacology and therapeutics</Title><ISOAbbreviation>Clin Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>A Phenotyping Tool for Seven Cytochrome P450 Enzymes and Two Transporters: Application to Examine the Effects of Clopidogrel and Gemfibrozil.</ArticleTitle><Pagination><StartPage>1732</StartPage><EndPage>1742</EndPage><MedlinePgn>1732-1742</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpt.3610</ELocationID><Abstract><AbstractText>Clinical cocktails for cytochrome P450 (CYP) phenotyping lack a marker for CYP2C8. We aimed to combine the CYP2C8 index drug repaglinide with the Geneva cocktail (caffeine/CYP1A2, bupropion/CYP2B6, flurbiprofen/CYP2C9, omeprazole/CYP2C19, dextromethorphan/CYP2D6, and midazolam/CYP3A4). We also included endogenous organic anion transporting polypeptide (OATP) 1B1 and 1B3 biomarkers glycochenodeoxycholate 3-O-glucuronide and glycochenodeoxycholate 3-sulfate, and investigated the CYP2C8 inhibition selectivity of clopidogrel and gemfibrozil with the full cocktail. In a five-phase randomized cross-over study, the following drugs were administered to 16 healthy volunteers: (i) repaglinide, (ii) the Geneva cocktail, (iii) repaglinide with the Geneva cocktail (full cocktail), (iv) clopidogrel followed by the full cocktail, and (v) gemfibrozil followed by the full cocktail. The Geneva cocktail increased repaglinide AUC<sub>0-23h</sub> 1.22-fold (90% confidence interval 1.04-1.44, P&#x2009;=&#x2009;0.033). The full cocktail accurately captured known inhibitory effects of clopidogrel on CYP2B6, CYP2C8, and CYP2C19 and that of gemfibrozil on CYP2C8. Gemfibrozil decreased the paraxanthine/caffeine AUC<sub>0-12h</sub> ratio by 23% (14-31%, P&#x2009;&lt;&#x2009;0.01) and increased caffeine AUC<sub>0-12h</sub> 1.20-fold (1.03-1.40, P&#x2009;=&#x2009;0.036). Gemfibrozil increased the metabolite-to-index drug AUC<sub>0-23h</sub> ratios of flurbiprofen, omeprazole, dextromethorphan, and midazolam 1.59-fold (1.32-1.92), 1.47-fold (1.34-1.61), 1.79-fold (1.23-2.59), and 2.1-fold (1.9-2.4), respectively, without affecting the index drug AUCs (P&#x2009;&lt;&#x2009;0.01). Gemfibrozil increased the AUC<sub>0-4h</sub> of glycochenodeoxycholate 3-O-glucuronide 1.33-fold (1.07-1.65, P&#x2009;=&#x2009;0.027). In conclusion, the combination of repaglinide, the Geneva cocktail and endogenous biomarkers for OATP1B1 and OATP1B3 yields a nine-in-one phenotyping tool. Apart from strong CYP2C8 inhibition, gemfibrozil weakly inhibits CYP1A2 and OATP1B1 and appears to impair the elimination of the metabolites of several CYP index drugs.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Clinical Pharmacology &amp; Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aurinsalo</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1915-6227</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lapatto-Reiniluoto</LastName><ForeName>Outi</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-2463-1862</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HUS Pharmacy, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurkela</LastName><ForeName>Mika</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4153-4143</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neuvonen</LastName><ForeName>Mikko</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7627-1638</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiiski</LastName><ForeName>Johanna I</ForeName><Initials>JI</Initials><Identifier Source="ORCID">0000-0002-4089-7209</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niemi</LastName><ForeName>Mikko</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4550-2189</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Tornio</LastName><ForeName>Aleksi</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5713-5692</Identifier><AffiliationInfo><Affiliation>Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Clinical Pharmacology, Turku University Hospital, Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Backman</LastName><ForeName>Janne T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0002-9577-2788</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>325667</GrantID><Agency>Academy of Finland</Agency><Country/></Grant><Grant><GrantID>8037</GrantID><Agency>Sigrid Jus&#xe9;lius Foundation</Agency><Country/></Grant><Grant><GrantID>TYH2019300</GrantID><Agency>State Funding for University-Level Health Research</Agency><Country/></Grant><Grant><GrantID>TYH2021304</GrantID><Agency>State Funding for University-Level Health Research</Agency><Country/></Grant><Grant><Agency>Hospital District of Helsinki and Uusimaa, Finland</Agency><Country/></Grant><Grant><GrantID>4697</GrantID><Agency>Finnish Medical Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Ther</MedlineTA><NlmUniqueID>0372741</NlmUniqueID><ISSNLinking>0009-9236</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>Q8X02027X3</RegistryNumber><NameOfSubstance UI="D015248">Gemfibrozil</NameOfSubstance></Chemical><Chemical><RegistryNumber>A74586SNO7</RegistryNumber><NameOfSubstance UI="D000077144">Clopidogrel</NameOfSubstance></Chemical><Chemical><RegistryNumber>9035-51-2</RegistryNumber><NameOfSubstance UI="D003577">Cytochrome P-450 Enzyme System</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065687">Cytochrome P-450 CYP2C8 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>668Z8C33LU</RegistryNumber><NameOfSubstance UI="C072379">repaglinide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002219">Carbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber><NameOfSubstance UI="D065727">Cytochrome P-450 CYP2C8</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C503999">SLCO1B1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D027381">Liver-Specific Organic Anion Transporter 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber><NameOfSubstance UI="C450259">CYP2C8 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000960">Hypolipidemic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015248" MajorTopicYN="Y">Gemfibrozil</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077144" MajorTopicYN="Y">Clopidogrel</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003577" MajorTopicYN="Y">Cytochrome P-450 Enzyme System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065687" MajorTopicYN="Y">Cytochrome P-450 CYP2C8 Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065727" MajorTopicYN="N">Cytochrome P-450 CYP2C8</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D027381" MajorTopicYN="N">Liver-Specific Organic Anion Transporter 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010975" MajorTopicYN="N">Platelet Aggregation Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000960" MajorTopicYN="Y">Hypolipidemic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declared no competing interests for this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>19</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>21</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39982209</ArticleId><ArticleId IdType="pmc">PMC12087695</ArticleId><ArticleId IdType="doi">10.1002/cpt.3610</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tornio, A. , Filppula, A.M. , Niemi, M. &amp; Backman, J.T. Clinical studies on drug&#x2010;drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation. Clin. Pharmacol. Ther. 105, 1345&#x2013;1361 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6563007</ArticleId><ArticleId IdType="pubmed">30916389</ArticleId></ArticleIdList></Reference><Reference><Citation>

Lenoir, C.

<i>et al</i>. Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva cocktail. Clin. Pharmacol. Ther.
109, 1668&#x2013;1676 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8247903</ArticleId><ArticleId IdType="pubmed">33341941</ArticleId></ArticleIdList></Reference><Reference><Citation>

Ryu, J.Y.

<i>et al</i>. Development of the &#x201c;Inje cocktail&#x201d; for high&#x2010;throughput evaluation of five human cytochrome P450 isoforms in&#xa0;vivo. Clin. Pharmacol. Ther.
82, 531&#x2013;540 (2007).
</Citation><ArticleIdList><ArticleId IdType="pubmed">17392720</ArticleId></ArticleIdList></Reference><Reference><Citation>

Turpault, S.

<i>et al</i>. Pharmacokinetic assessment of a five&#x2010;probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br. J. Clin. Pharmacol.
68, 928&#x2013;935 (2009).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810805</ArticleId><ArticleId IdType="pubmed">20002088</ArticleId></ArticleIdList></Reference><Reference><Citation>

Bosilkovska, M.

<i>et al</i>. Evaluation of mutual drug&#x2010;drug interaction within Geneva cocktail for cytochrome P450 phenotyping using innovative dried blood sampling method. Basic Clin. Pharmacol. Toxicol.
119, 284&#x2013;290 (2016).
</Citation><ArticleIdList><ArticleId IdType="pubmed">27009433</ArticleId></ArticleIdList></Reference><Reference><Citation>

Bosilkovska, M.

<i>et al</i>. Geneva cocktail for cytochrome p450 and P&#x2010;glycoprotein activity assessment using dried blood spots. Clin. Pharmacol. Ther.
96, 349&#x2013;359 (2014).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4151019</ArticleId><ArticleId IdType="pubmed">24722393</ArticleId></ArticleIdList></Reference><Reference><Citation>

Donzelli, M.

<i>et al</i>. The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots. Clin. Pharmacokinet.
53, 271&#x2013;282 (2014).
</Citation><ArticleIdList><ArticleId IdType="pubmed">24218006</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosilkovska, M. , Magliocco, G. , Desmeules, J. , Samer, C. &amp; Daali, Y. Interaction between fexofenadine and CYP phenotyping probe drugs in Geneva cocktail. J. Pers. Med. 9, 45 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6963818</ArticleId><ArticleId IdType="pubmed">31581637</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhr, U. , Jetter, A. &amp; Kirchheiner, J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the &#x201c;cocktail&#x201d; approach. Clin. Pharmacol. Ther. 81, 270&#x2013;283 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17259951</ArticleId></ArticleIdList></Reference><Reference><Citation>

Rollason, V.

<i>et al</i>. Safety of the Geneva cocktail, a cytochrome P450 and P&#x2010;glycoprotein phenotyping cocktail, in healthy volunteers from three different geographic origins. Drug Saf.
43, 1181&#x2013;1189 (2020).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7575470</ArticleId><ArticleId IdType="pubmed">32851583</ArticleId></ArticleIdList></Reference><Reference><Citation>Paludetto, M.N. , Kurkela, M. , Kahma, H. , Backman, J.T. , Niemi, M. &amp; Filppula, A.M. Hydroxychloroquine is metabolized by cytochrome P450 2D6, 3A4, and 2C8, and inhibits cytochrome P450 2D6, while its metabolites also inhibit cytochrome P450 3A in&#xa0;vitro. Drug Metab. Dispos. 51, 293&#x2013;305 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36446607</ArticleId></ArticleIdList></Reference><Reference><Citation>Backman, J.T. , Filppula, A.M. , Niemi, M. &amp; Neuvonen, P.J. Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol. Rev. 68, 168&#x2013;241 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26721703</ArticleId></ArticleIdList></Reference><Reference><Citation>

Tornio, A.

<i>et al</i>. Glucuronidation converts clopidogrel to a strong time&#x2010;dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug&#x2010;drug interactions. Clin. Pharmacol. Ther.
96, 498&#x2013;507 (2014).
</Citation><ArticleIdList><ArticleId IdType="pubmed">24971633</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemi, M. , Backman, J.T. , Neuvonen, M. &amp; Neuvonen, P.J. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46, 347&#x2013;351 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12687332</ArticleId></ArticleIdList></Reference><Reference><Citation>Shitara, Y. , Hirano, M. , Sato, H. &amp; Sugiyama, Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)&#x2010;mediated hepatic uptake and CYP2C8&#x2010;mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug&#x2010;drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311, 228&#x2013;236 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15194707</ArticleId></ArticleIdList></Reference><Reference><Citation>Tornio, A. , Neuvonen, P.J. , Niemi, M. &amp; Backman, J.T. Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. Expert Opin. Drug Metab. Toxicol. 13, 83&#x2013;95 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27548563</ArticleId></ArticleIdList></Reference><Reference><Citation>

Tamraz, B.

<i>et al</i>. OATP1B1&#x2010;related drug&#x2010;drug and drug&#x2010;gene interactions as potential risk factors for cerivastatin&#x2010;induced rhabdomyolysis. Pharmacogenet. Genomics
23, 355&#x2013;364 (2013).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3894639</ArticleId><ArticleId IdType="pubmed">23652407</ArticleId></ArticleIdList></Reference><Reference><Citation>

Neuvonen, M.

<i>et al</i>. Identification of glycochenodeoxycholate 3&#x2010;O&#x2010;glucuronide and Glycodeoxycholate 3&#x2010;O&#x2010;glucuronide as highly sensitive and specific OATP1B1 biomarkers. Clin. Pharmacol. Ther.
109, 646&#x2013;657 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7983942</ArticleId><ArticleId IdType="pubmed">32961594</ArticleId></ArticleIdList></Reference><Reference><Citation>

Orozco, C.C.

<i>et al</i>. Characterization of bile acid sulfate conjugates as substrates of human organic anion transporting polypeptides. Mol. Pharm.
20, 3020&#x2013;3032 (2023).
</Citation><ArticleIdList><ArticleId IdType="pubmed">37134201</ArticleId></ArticleIdList></Reference><Reference><Citation>Rago, B. , Tierney, B. , Rodrigues, A.D. , Holliman, C.L.H. &amp; Ramanathan, R. A multiplex HRMS assay for quantifying selected human plasma bile acids as candidate OATP biomarkers. Bioanalysis 10, 645&#x2013;657 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29749252</ArticleId></ArticleIdList></Reference><Reference><Citation>

Kiiski, J.I.

<i>et al</i>. Solanidine is a sensitive and specific dietary biomarker for CYP2D6 activity. Hum. Genomics
18, 11 (2024).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10835938</ArticleId><ArticleId IdType="pubmed">38303026</ArticleId></ArticleIdList></Reference><Reference><Citation>

Piha, M.O.W.

<i>et al</i>. Candesartan has no clinically meaningful effect on the plasma concentrations of cytochrome P450 2C8 substrate repaglinide in humans. Drug Metab. Dispos.
52, 1388&#x2013;1395 (2024).
</Citation><ArticleIdList><ArticleId IdType="pubmed">39486868</ArticleId></ArticleIdList></Reference><Reference><Citation>

Litonius, K.

<i>et al</i>. Value of pharmacogenetic testing assessed with real&#x2010;world drug utilization and genotype data. Clin. Pharmacol. Ther.
117, 278&#x2013;288 (2025).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11652815</ArticleId><ArticleId IdType="pubmed">39365028</ArticleId></ArticleIdList></Reference><Reference><Citation>

Richter, T.

<i>et al</i>. Potent mechanism&#x2010;based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J. Pharmacol. Exp. Ther.
308, 189&#x2013;197 (2004).
</Citation><ArticleIdList><ArticleId IdType="pubmed">14563790</ArticleId></ArticleIdList></Reference><Reference><Citation>Turpeinen, M. , Tolonen, A. , Uusitalo, J. , Jalonen, J. , Pelkonen, O. &amp; Laine, K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin. Pharmacol. Ther. 77, 553&#x2013;559 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15961986</ArticleId></ArticleIdList></Reference><Reference><Citation>

Kahma, H.

<i>et al</i>. An automated cocktail method for in&#xa0;vitro assessment of direct and time&#x2010;dependent inhibition of nine major cytochrome P450 enzymes &#x2013; application to establishing CYP2C8 inhibitor selectivity. Eur. J. Pharm. Sci.
162, 105810 (2021).
</Citation><ArticleIdList><ArticleId IdType="pubmed">33753217</ArticleId></ArticleIdList></Reference><Reference><Citation>

Ahmad, L.

<i>et al</i>. Effect of clopidogrel on the hydroxylation and sulfoxidation of omeprazole: a single dose study in healthy human volunteers. EXCLI J.
16, 321&#x2013;327 (2017).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5427475</ArticleId><ArticleId IdType="pubmed">28507476</ArticleId></ArticleIdList></Reference><Reference><Citation>

Chen, B.L.

<i>et al</i>. Clopidogrel inhibits CYP2C19&#x2010;dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms. J. Clin. Pharmacol.
49, 574&#x2013;581 (2009).
</Citation><ArticleIdList><ArticleId IdType="pubmed">19398604</ArticleId></ArticleIdList></Reference><Reference><Citation>Itkonen, M.K. , Tornio, A. , Neuvonen, M. , Neuvonen, P.J. , Niemi, M. &amp; Backman, J.T. Clopidogrel has no clinically meaningful effect on the pharmacokinetics of the organic anion transporting polypeptide 1B1 and cytochrome P450 3A4 substrate simvastatin. Drug Metab. Dispos. 43, 1655&#x2013;1660 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26329790</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen, X. , Wang, J.S. , Backman, J.T. , Kivisto, K.T. &amp; Neuvonen, P.J. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab. Dispos. 29, 1359&#x2013;1361 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11602509</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemi, M. , Neuvonen, P.J. &amp; Kivisto, K.T. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin. Pharmacol. Ther. 70, 439&#x2013;445 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11719730</ArticleId></ArticleIdList></Reference><Reference><Citation>Lilja, J.J. , Backman, J.T. &amp; Neuvonen, P.J. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. Br. J. Clin. Pharmacol. 59, 433&#x2013;439 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1884811</ArticleId><ArticleId IdType="pubmed">15801938</ArticleId></ArticleIdList></Reference><Reference><Citation>Tornio, A. , Niemi, M. , Neuvonen, P.J. &amp; Backman, J.T. Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen. Eur. J. Clin. Pharmacol. 63, 463&#x2013;469 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17333159</ArticleId></ArticleIdList></Reference><Reference><Citation>

Duthaler, U.

<i>et al</i>. The activity of members of the UDP&#x2010;glucuronosyltransferase subfamilies UGT1A and UGT2B is impaired in patients with liver cirrhosis. Clin. Pharmacokinet.
62, 1141&#x2013;1155 (2023).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10386950</ArticleId><ArticleId IdType="pubmed">37328712</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudesheim, S. , Selzer, D. , Fuhr, U. , Schwab, M. &amp; Lehr, T. Physiologically&#x2010;based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups. CPT Pharmacometrics Syst. Pharmacol. 11, 494&#x2013;511 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9007601</ArticleId><ArticleId IdType="pubmed">35257505</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo, K.A. , Bae, S.K. , Choi, Y.K. , Choi, C.S. , Liu, K.H. &amp; Shin, J.G. Metabolism of 1&#x2032;&#x2010; and 4&#x2010;hydroxymidazolam by glucuronide conjugation is largely mediated by UDP&#x2010;glucuronosyltransferases 1A4, 2B4, and 2B7. Drug Metab. Dispos. 38, 2007&#x2013;2013 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20713656</ArticleId></ArticleIdList></Reference><Reference><Citation>Prueksaritanont, T. , Tang, C. , Qiu, Y. , Mu, L. , Subramanian, R. &amp; Lin, J.H. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos. 30, 1280&#x2013;1287 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12386136</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato, Y. , Nakajima, M. , Oda, S. , Fukami, T. &amp; Yokoi, T. Human UDP&#x2010;glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their contribution. Drug Metab. Dispos. 40, 240&#x2013;248 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22028316</ArticleId></ArticleIdList></Reference><Reference><Citation>

Gan, J.

<i>et al</i>. Repaglinide&#x2010;gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Br. J. Clin. Pharmacol.
70, 870&#x2013;880 (2010).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3014070</ArticleId><ArticleId IdType="pubmed">21175442</ArticleId></ArticleIdList></Reference><Reference><Citation>Iga, K. &amp; Kiriyama, A. Interplay of UDP&#x2010;glucuronosyltransferase and CYP2C8 for CYP2C8 mediated drug oxidation and its impact on drug&#x2010;drug interaction produced by standardized CYP2C8 inhibitors, clopidogrel and gemfibrozil. Clin. Pharmacokinet. 63, 43&#x2013;56 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">37921907</ArticleId></ArticleIdList></Reference><Reference><Citation>Itkonen, M.K. , Tornio, A. , Neuvonen, M. , Neuvonen, P.J. , Niemi, M. &amp; Backman, J.T. Clopidogrel and gemfibrozil strongly inhibit the CYP2C8&#x2010;dependent formation of 3&#x2010;Hydroxydesloratadine and increase desloratadine exposure in humans. Drug Metab. Dispos. 47, 377&#x2013;385 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30630815</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson, A. , Kazmi, F. , Buckley, D.B. , Yerino, P. , Ogilvie, B.W. &amp; Paris, B.L. System&#x2010;dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes. Drug Metab. Pharmacokinet. 25, 16&#x2013;27 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20208386</ArticleId></ArticleIdList></Reference><Reference><Citation>

Watanabe, T.

<i>et al</i>. Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug&#x2010;drug interaction involving organic anion transporter 3 in humans by in&#xa0;vitro uptake experiments. Drug Metab. Dispos.
39, 1031&#x2013;1038 (2011).
</Citation><ArticleIdList><ArticleId IdType="pubmed">21383204</ArticleId></ArticleIdList></Reference><Reference><Citation>Backman, J.T. , Kyrklund, C. , Kivisto, K.T. , Wang, J.S. &amp; Neuvonen, P.J. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin. Pharmacol. Ther. 68, 122&#x2013;129 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10976543</ArticleId></ArticleIdList></Reference><Reference><Citation>

Ho, R.H.

<i>et al</i>. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology
130, 1793&#x2013;1806 (2006).
</Citation><ArticleIdList><ArticleId IdType="pubmed">16697742</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalliokoski, A. , Backman, J.T. , Kurkinen, K.J. , Neuvonen, P.J. &amp; Niemi, M. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin. Pharmacol. Ther. 84, 488&#x2013;496 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19238654</ArticleId></ArticleIdList></Reference><Reference><Citation>

Tornio, A.

<i>et al</i>. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism&#x2010;based inhibition of CYP2C8 in&#xa0;vivo. Clin. Pharmacol. Ther.
84, 403&#x2013;411 (2008).
</Citation><ArticleIdList><ArticleId IdType="pubmed">18388877</ArticleId></ArticleIdList></Reference><Reference><Citation>Honkalammi, J. , Niemi, M. , Neuvonen, P.J. &amp; Backman, J.T. Dose&#x2010;dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. Drug Metab. Dispos. 39, 1977&#x2013;1986 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21778352</ArticleId></ArticleIdList></Reference><Reference><Citation>

Niemi, M.

<i>et al</i>. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther.
77, 468&#x2013;478 (2005).
</Citation><ArticleIdList><ArticleId IdType="pubmed">15961978</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi, Y.A. , Jordan, S. , King&#x2010;Ahmad, A. , West, M.A. &amp; Varma, M.V.S. Mechanistic determinants of Daprodustat drug&#x2010;drug interactions and pharmacokinetics in hepatic dysfunction and chronic kidney disease: significance of OATP1B&#x2010;CYP2C8 interplay. Clin. Pharmacol. Ther. 115, 1336&#x2013;1345 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38404228</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39798901</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0720</ISSN><JournalIssue CitedMedium="Internet"><Volume>206</Volume><PubDate><Year>2025</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</Title><ISOAbbreviation>Eur J Pharm Sci</ISOAbbreviation></Journal><ArticleTitle>Drug interaction evaluation of the novel phosphodiesterase type 5 inhibitor tunodafil (youkenafil): Effects of tunodafil on omeprazole pharmacokinetics based on CYP2C19 gene polymorphism, and effects of ritonavir on tunodafil pharmacokinetics.</ArticleTitle><Pagination><StartPage>107010</StartPage><MedlinePgn>107010</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejps.2025.107010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0928-0987(25)00009-0</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To evaluate the drug-drug interactions (DDI) of tunodafil (youkenafil), a novel phosphodiesterase type 5 inhibitor, its inhibitory effects on CYP450 enzymes in vitro and its clinical trials in combination with ritonavir or omeprazole were conducted.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The inhibitory effect of tunodafil on seven major CYP450 enzymes in human liver microsomes was investigated by probe substrate method. The effect of tunodafil on the pharmacokinetics of omeprazole (CYP2C19 substrate) in 40 healthy subjects, who received a single dose of 40 mg omeprazole in combination with tunodafil on the day 8 after taking 100 mg tunodafil daily for 7 days, was assessed based on CYP2C19 genotypes. The clinical DDI of ritonavir (potent CYP3A4 inhibitor) on tunodafil was studied in 28 healthy subjects who received a single dose of 50 mg tunodafil in combination with ritonavir on the day 6 after taking ritonavir twice a day for 5 days.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Tunodafil showed moderate inhibition on CYP2C19 and CYP3A4/5 in vitro. When co-administration omeprazole with tunodafil, the AUC of omeprazole in the Extensive, Intermediate and Poor Metabolizers increased by 26 %, 37 % and 21 %, respectively. After co-administration tunodafil with ritonavir, ritonavir increased the AUC and C<sub>max</sub> of tunodafil in human by about 78- fold and 13-fold respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Tunodafil slightly increased omeprazole exposure in the Extensive and Intermediate Metabolizers of CYP2C19, but had no significant effect on omeprazole exposure in the Poor Metabolizers. Ritonavir could strongly inhibit the metabolism of tunodafil, and the combination of tunodafil with ritonavir should be prohibited.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Keli</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 211198, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Juefang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nanjing Jiening Pharmaceutical Technology Co., LTD, Nanjing 211000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Minlu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 211198, China; Nanjing Clinical Technology Laboratories Inc., Nanjing 211100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xianjing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 211198, China; Nanjing Clinical Technology Laboratories Inc., Nanjing 211100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Drug Clinical Trial Center, The First Affiliated Hospital of Bengbu Medical College, Bengbu, An-hui 233000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Qinxin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 211198, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yuanxun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Phase I Clinical Trials Unit, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China. Electronic address: 2787487990@qq.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Phase I Clinical Trials Unit, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China. Electronic address: juanli2003@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 211198, China. Electronic address: dingli@cpu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur J Pharm Sci</MedlineTA><NlmUniqueID>9317982</NlmUniqueID><ISSNLinking>0928-0987</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber><NameOfSubstance UI="D065731">Cytochrome P-450 CYP2C19</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>KG60484QX9</RegistryNumber><NameOfSubstance UI="D009853">Omeprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber><NameOfSubstance UI="C045793">CYP2C19 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065689">Cytochrome P-450 CYP2C19 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065731" MajorTopicYN="Y">Cytochrome P-450 CYP2C19</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="Y">Ritonavir</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009853" MajorTopicYN="Y">Omeprazole</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="Y">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008862" MajorTopicYN="N">Microsomes, Liver</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="Y">Imidazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065689" MajorTopicYN="N">Cytochrome P-450 CYP2C19 Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CYP2C19 polymorphism</Keyword><Keyword MajorTopicYN="N">Drug-drug interaction</Keyword><Keyword MajorTopicYN="N">Omeprazole</Keyword><Keyword MajorTopicYN="N">Pharmacokinetics</Keyword><Keyword MajorTopicYN="N">Ritonavir</Keyword><Keyword MajorTopicYN="N">Tunodafil (youkenafil)</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors have no competing interests to declare that are relevant to the content of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>7</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>12</Day><Hour>15</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>11</Day><Hour>19</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39798901</ArticleId><ArticleId IdType="doi">10.1016/j.ejps.2025.107010</ArticleId><ArticleId IdType="pii">S0928-0987(25)00009-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>